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ABSTRACT 
Binge drinking is one of the most dangerous types of alcohol consumption; over 
38% of young adults and 24% of adults 26 years of age and older report binge drinking.  
Motivation to binge drink may come from comorbidity with pain conditions.  
Considerable animal evidence shows a biphasic relationship between alcohol and pain 
with intoxication-induced hypoalgesia (decreased sensitivity to painful stimuli) followed 
by withdrawal-induced hyperalgesia (increased sensitivity to painful stimuli).  The anti-
reward model of addiction suggests rewarding aspects of intoxication (e.g., analgesia) 
drive initial consumption.  As drinking continues, anti-reward withdrawal aspects (e.g., 
hyperalgesia) activate brain stress axes and motivate craving and consumption.  
Following withdrawal, the third phase is anticipation of alcohol.  Animal models of 
alcohol withdrawal-induced muscle mechanical hyperalgesia suggest the hyperalgesia 
results from changes in peripheral nociceptors mediated by increased release of stress 
hormones.  Consistent with these findings, our laboratory recently observed withdrawal-
induced muscle mechanical hyperalgesia and increased circulating levels of epinephrine 
in young adult binge drinkers using a between-subjects design. 
The current study used a mixed between-within-subjects design to assess muscle 
mechanical sensitivity, cutaneous thermal sensitivity, and neurogenic inflammation, as 
well as a measure of central sensitization of pain — thermal temporal summation of 
second pain.  Blood was collected to investigate moderation by epinephrine and pro-
inflammatory IL-6.  Individuals were prescreened for alcohol use and categorized as 
iii 
moderate and binge drinkers using National Institute on Alcohol Abuse and Alcoholism 
(NIAAA) binge drinking criteria.  Participants made two visits: one during abstinence 
(no alcohol within previous 48 hours) and one during withdrawal (drinking within 
previous 48 hours).  We found binge drinkers reported more alcohol use before the 
withdrawal state, greater hangover symptoms, and more alcohol use disorder symptoms.  
Importantly, we found that participants in the withdrawal state reported mechanical 
hyperalgesia in skeletal muscle, partially supporting previous results in animals and our 
laboratory.  In parallel, we found participants in withdrawal reported reduced cutaneous 
thermal sensitivity on multiple measures.  Pain sensitivity results were predominantly 
driven by effects in male participants.  Participants in withdrawal also reported more 
dominance and less anxiety and negative affect but exhibited greater 
psychophysiological responses.  Several hypotheses for future research are presented. 
iv 
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INTRODUCTION
“Here’s to alcohol: the cause of, and answer to, all of life’s problems” - Matt 
Groening.  This quote conveys both the danger and allure of alcohol consumption.  It 
alludes to the use of alcohol as a remedy for life’s problems, including a long day at 
work or a traumatic event,  in spite of the harms associated with it.
1,73
  One understudied 
application of this quote is pain, to which the quote may be revised to read: ‘Here’s to 
alcohol: the cause of, and answer to, one’s pains’. 
Problem of Binge Drinking 
In particular, one of the most dangerous types of drinking is binge drinking, 
defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as five or 
more drinks for males and four or more drinks for females within 2 hours.
71
  Excessive 
alcohol consumption, including binge drinking, has contributed to approximately 1 in 10 
deaths of working-age adults in the U.S.
92
 and has contributed to the prevalence of other 
health conditions.
109
  A recent national survey reports that 24.2% of individuals aged 12 
and over were estimated to binge drink during the past 30 days.
96
  Binge drinking may 
be most prevalent in young adulthood with 38.4% of young adults (age 18-25) reporting 
binge drinking, which is greater than the 5% of adolescents and 24.2% of adults aged 26 
and over.
96
  Binge drinking during young adulthood may also have long-term 
consequences later in life.
31
  By investigating binge withdrawal-induced increases in
2 
pain sensitivity to already painful stimuli (hyperalgesia) in young adults, we may be able 
to prevent or treat hyperalgesia and chronic pain in the early stages before long-term 
effects, including alcohol dependence and alcohol-induced peripheral neuropathy, have 
been established. 
Binge drinking and pain are often comorbid conditions and may be related.  
Studies report that between 20-25% of adults report using alcohol to self-medicate their 
pain with a positive dose-response relationship between greater self-medication with 
alcohol and greater pain frequency.
81
  Similar results were found in a population of
military veterans, where 24% of individuals reported using alcohol to manage pain.
39
For individuals being treated for alcohol use disorders, pain significantly predicted 
increased risk of heavy drinking during and after treatment for alcohol use disorders.
106
Reducing pain has also been shown to decrease the odds of relapse following treatment 
by 85%.
48
  This relationship between pain and alcohol use may not be the case for
everyone with chronic pain,
61,98
 thus it is important to understand the mechanisms and
individual difference variables that predict who will have comorbid pain with alcohol 
abuse. 
Pain and Alcohol Dependence 
Alcohol consumption can lead to subjective stimulation during the increase in 
blood alcohol content and subjective sedation during the decrease in blood alcohol 
content.
66
  Similarly, considerable animal evidence suggests  alcohol consumption leads
to an initial reduction in pain sensitivity (analgesia) followed by heightened pain 
sensitivity (hyperalgesia).
25,27,35,37
  Most research examining alcohol’s effects on pain are
3 
from animal studies that focus on the acute effects of one to three injections of 
alcohol.
17,33,47,50
  These studies suggest that short-term use of alcohol is associated with
reduced thermal pain (thermal hypoalgesia).  However, other studies use chronic 
administration of alcohol over multiple days by including alcohol in the animal’s 
diet.
22,27,35,37
  These studies show that with chronic administration of alcohol, animals
show thermal hypoalgesia during intoxication
35,37
 and thermal and mechanical
hyperalgesia during withdrawal.
22,27,35,37
In humans, relatively little research has investigated alcohol’s effects on pain.  
Most studies have examined the acute effects of alcohol on shock-induced pain.
74,95
  One
study inspected thermal pain sensitivity in alcohol-dependent individuals before, during, 
and after alcohol use disorder treatment.
49
  Research from our laboratory was the first to
investigate binge withdrawal-induced mechanical, thermal, and inflammatory 
hyperalgesia in young adults.  One study used a between-subjects design, which did not 
account for within-subject variability, and observed mechanical muscle hyperalgesia in 
binge drinkers during withdrawal following a natural binge.  To reduce variability and 
experimentally control alcohol consumption, a second study used a within-subjects 
design with laboratory administration of alcohol.  However, the legally allowable dose 
of alcohol administered was insufficient to induce withdrawal symptoms comparable to 
a natural binge and thus no differences were observed in muscle pain.
114
Animal models have shown that alcohol withdrawal-induced hyperalgesia may 
be dependent on the type of alcohol use and pain modality tested.  Following a 10 day 
continuous diet of alcohol, cutaneous heat hyperalgesia emerged at three hours, peaked 
4 
at 6-12 hours, and disappeared at 36 hours following cessation of drinking.
35
Importantly, withdrawal from a single episode of alcohol use induced muscle 
mechanical hyperalgesia that strengthened over time and lasted at least 15 days 
following cessation.
27
  Muscle mechanical hyperalgesia was exaggerated after a second
episode of alcohol administration and withdrawal.  These results suggest that repeated 
episodes of alcohol use and withdrawal more quickly induce a state of worsening 
hyperalgesia that lasts longer than from continuous drinking. 
The bi-phasic effect of alcohol on pain may lead to self-medication and underlie 
the relationship between alcohol and pain.
28,38
  People who have a pain condition may
drink for the acute analgesic effect of alcohol.
39,81
  However, when the individual is in
withdrawal, the resulting hyperalgesia and increase in pain may increase their motivation 
to drink more.  In one model of addiction linking alcohol use and dependence to 
pain,
28,60
 people originally drink for the acute and rewarding positive mood state
(euphoria) and analgesia that result from binge intoxication and are mediated by neural 
plasticity in specific brain regions.  Indeed, greater positive stimulating effects of alcohol 
have been associated with greater risk for binge drinking.
56
  This positive rewarding
state is the “a” component of the opponent process (Fig. 1B, bottom) and is mediated by 
release of dopamine and opioid peptides in the ventral striatum of the basal ganglia.
60
  In
a human neuroimaging study, greater endorphin release in the nucleus accumbens in 
naïve and heavy drinkers and greater endorphin release in the orbitofrontal cortex in 
heavy drinkers during consumption was related to greater feelings of pleasure.
69
  The
rewarding euphoria and analgesia is followed by the anti-reward withdrawal state of 
5 
negative affect (dysphoria) and hyperalgesia, comprising the opposing “b” process.  
After the negative effects of withdrawal, the individual may become preoccupied and 
anticipate the next binge intoxication stage for its rewarding positive mood and 
analgesia.  This third stage is mediated via dysregulation of the prefrontal cortex 
executive control circuits.
60
  Over time, continued binge drinking may lead to a decrease
in the brain’s reward system which means the individual feels less positive, rewarding 
effects of the “a” process.  Simultaneously, these individuals also feel an increase in the 
anti-reward system, or “b” process, which means the individual feels increasing negative 
motivational effects, including negative affect.  Over the course of multiple binge 
withdrawal cycles, the original euphoria and analgesia they felt is slowly replaced by 
increasing amounts of dysphoria and hyperalgesia during withdrawal.  Although the 
individual may continue to drink for the positive rewarding euphoria and analgesia 
(positive reinforcement), eventually, they will binge drink to escape the dysphoria 
(negative reinforcement) as they no longer feel the euphoria and analgesia.  While this 
model suggests that alcohol withdrawal-induced negative affect and hyperalgesia 
contribute to the development of alcohol dependence, it remains unclear whether this 
model and its mechanisms translate to humans. 
6 
Figure 1.  Model of (A) three stages of addiction and (B) the temporal development of alcohol 
dependence.
38
  Modified from Dialogues in Clinical Neuroscience with the permission of the publisher 
(Institut La Conference Hippocrate, Suresnes, France), George O, Koob. Individual differences in the 
neuropsychopathology of addiction. Dialogues Clin Neurosci. 2017;19(3):217-229, © AICH-Servier 
Research Group. 
Importantly, the withdrawal state is mediated by decreased activity in reward 
systems of the ventral striatum and an increase in the anti-reward systems of the 
hypothalamic-pituitary-adrenal stress (HPA)
2
 axis and the brain stress systems including
the nucleus accumbens, bed nucleus of the stria terminalis, central nucleus of the 
amygdala, among others that are collectively known as the extended amygdala.
60
  This
increase in stress system activity is associated with increased corticotropin-releasing 
factor and norepinephrine, which seem to underlie withdrawal-induced anxiety-like 
behaviors and self-administration of alcohol.
58,59
  This increase in stress activity during
withdrawal may explain the effects of withdrawal-induced mechanical hyperalgesia 
found in animal models
25,27
 and the increased craving and self-administration of
alcohol.
34





Though understudied in humans, alcohol withdrawal-induced hyperalgesia is a 
well-established phenomenon in animal models.  This provides researchers the ability to 
more invasively assess mechanisms. 
One such animal model of alcohol-induced mechanical muscle sensitivity is 
important in understanding the influence of musculoskeletal pain –  one of the most 
common patient complaints, including in peripheral neuropathies such as alcohol-
induced peripheral neuropathy.
51
  This model of alcohol-induced mechanical muscle
hyperalgesia has rats consume a liquid diet containing 6.5% ethanol for 4 consecutive 
days to mimic 0.08% blood alcohol content or levels found in binge drinking, followed 
by 3 consecutive days of withdrawal.
27
  One 7-day cycle of this diet is sufficient to
induce a state of prolonged mechanical hyperalgesia (i.e., lowered muscle pressure pain 
threshold) in the hindpaw that is exaggerated by a second cycle.
27
  Adrenal
medullectomy, thus removing the body’s supply of epinephrine, blocked the induction 
and maintenance of alcohol-induced mechanical muscle hyperalgesia.
25
  This
hyperalgesia was reinstated following injection of epinephrine used to mimic stress.  
Likewise, local intradermal injection of the glucocorticoid receptor antagonist, 
RU38486, blocked the mechanical muscle hyperalgesia during both induction and 
maintenance.
25
  These results suggest that alcohol withdrawal-induced hyperalgesia was
mediated by increased levels of circulating epinephrine and corticosterone in the 
periphery.
25
  In addition, alcohol withdrawal-induced hyperalgesia was dependent on the




 and protein kinase A (PKA) in female rats.
23
  These results suggest that
repeated cycles of alcohol use and withdrawal tonically activate the stress axes along 
with a cellular mechanism in the peripheral nociceptors are needed to embed alcohol 
withdrawal-induced mechanical hyperalgesia.  Other studies found  the role of gamma-
aminobutyric acid in alcohol-induced analgesia and adenosine receptors, calcium 
channels, and PKC in alcohol withdrawal-induced hyperalgesia.
36
A potential mechanism of alcohol withdrawal-induced hyperalgesia may be 
peripheral levels of interleukin-6 (IL-6).  Animal research has shown that a localized 
intramuscular injection of IL-6 induces mechanical muscle hyperalgesia, that is blocked 
by administration of an intrathecal injection of antisense to the glycoprotein 130.
24
Additionally, IL-6 was necessary for the expression of mechanical muscle hyperalgesia 
in a model of early life stress-induced hyperalgesia.
26
  This model of stress-induced
hyperalgesia is mediated by circulating epinephrine, similar to alcohol-induced 
mechanical muscle hyperalgesia.
25,27
Another potential mechanism is inflammation stemming from neuronal activity 
(neurogenic inflammation).  This erythematous flare response stems from antidromic 
activity in peripheral neurons that leads to a localized release of calcitonin gene related 
peptide and substance P.
88
  These neural mediators lead to increased capillary
permeability
15
 and plasma extravasation and edema.
87
  Topical alcohol can induce
neurogenic inflammation.
99
  Stress reduction techniques have been shown to protect
against an increase in neurogenic inflammation
85
 and be associated with a decrease in
neurogenic inflammation, perceived stress, and cortisol.
86
  Given the stress-inducing
9 
nature of alcohol withdrawal,
58,59
 it is possible that alcohol consumption could lead to a
state of heightened neurogenic inflammatory tone that partially explains binge 
withdrawal-induced hyperalgesia. 
Few studies have experimentally investigated withdrawal-induced hyperalgesia 
in humans.  One study used a between-subjects design with one group of middle-aged 
male participants followed through treatment at a facility for acute alcohol detoxification 
and a second group of males 2-3 months sober after detoxification.
49
  This study found
that for males admitted for acute alcohol treatment, initially increased sensitivity to 
thermal stimuli decreased with abstinence.  However, that study used a population of 
middle-aged males individuals already being treated for an alcohol use disorder and 
therefore may not translate to a younger population of both genders in which alcohol use 
disorders may not yet be established.  In a separate between-subjects study of young 
adults with histories of either abstention, moderate drinking, or binge drinking, with or 
without alcohol consumption in the prior 48 hours, our laboratory found a lower pressure 
pain threshold was found in binge drinkers that was exaggerated by withdrawal.
114
  In
testing potential mechanisms, binge drinkers during abstention showed greater baseline 
epinephrine than moderate drinkers during abstention.  This was the first study to 
investigate binge withdrawal-induced hyperalgesia in humans and is consistent with 
muscle mechanical hyperalgesia that was mediated by increased epinephrine in an 
animal model of alcohol withdrawal.
22,25,27
  Both of these studies focused on static
measures of pain sensitivity, which may not predict the development of chronic pain as 
well as dynamic measures that reflect the mechanisms of central sensitization.
42,110
10 
The mechanisms underlying binge withdrawal-induced hyperalgesia likely 
include mechanisms of sensitization occurring in both the peripheral and central nervous 
systems.  Pain is often a result of activation of peripheral nociceptors.  These nociceptors 
terminate in the dorsal horn of the spinal cord and subsequent second-order neurons 
project up the spinal cord to the brain.  Increased activity from the peripheral nociceptors 
can reversibly increase the excitability and efficacy of the synapses in the dorsal horn of 
the spinal cord in a process termed central sensitization.
7,107,108
  This phenomenon may
also reflect sensitization of brain areas including the thalamus and amygdala, which have 




 respectively.  In the
brain, ascending spinal neurons transmit signals to brain areas associated with the 
sensory and affective dimensions of pain.
80
  Neuroimaging and anatomical studies have
implicated cortical and subcortical areas in the experience of pain, including areas that 
have connections to afferent neurons such as the primary and secondary somatosensory 
cortices, insula, prefrontal cortex, and thalamus.
4
  Further research has linked patterns of
brain activity in response to the painful stimulus in areas including the thalamus, 
posterior and anterior insulae, and periaqueductal gray, as well as a different pattern of 
brain activity involved in neural contributions independent of stimulus intensity.
80,101
Animal models of alcohol withdrawal-induced hyperalgesia suggest that this 
form of withdrawal-induced hyperalgesia is a result of increased systemic epinephrine 
and corticosterone stress hormones lead to sensitization of the peripheral afferents.  
Alternatively, or in addition to, sensitization of the peripheral nervous system, activity 
from the peripheral nervous system may sensitize second-order neurons in the spinal 
11 
cord or more supraspinal areas in humans.  Evidence for the possible role of central 
nervous system mechanisms in binge withdrawal-induced hyperalgesia may be found in 
the dysregulation of brain areas involved in both alcohol dependence and pain.
5,28
As discussed earlier, one study from our laboratory used a between-subjects 
model to investigate binge withdrawal-induced hyperalgesia after naturally occurring 
alcohol use (i.e., we gave no instructions with regard to the amount that they should 
drink nor when to drink).  We found binge drinkers in abstinence reported muscle 
mechanical hyperalgesia compared to moderate drinkers in abstinence and these effects 
were exaggerated in binge drinkers in withdrawal.
114
  We also found increased
epinephrine in binge drinkers during abstention when compared to moderate drinkers 
during abstention.  These results are consistent with the pattern of results observed in an 
animal model of binge withdrawal-induced muscle mechanical hyperalgesia.
22,25,27
  In a
follow-up study, we administered alcohol to young adults until a breath alcohol content 
of 0.08% was achieved.
114
  However, we failed to find the main effect of group on
mechanical hyperalgesia and did not show an effect of group on capsaicin-induced 
measures of central sensitization likely due to ethical limitations that did not allow us to 
administer alcohol doses comparable to participants’ normal levels of alcohol 
consumption.
114
  This explanation was supported by the lower acute hangover symptoms
experienced in the second study compared to the first study.  These results suggest that 
allowing participants to choose when they binge drink based on their normal routine 
induces hangover symptoms needed to find mechanical hyperalgesia.  Whether increased 
12 
mechanical muscle pain sensitivity is associated with enhanced central sensitization is 
not known. 
Thesis 
Building on the foregoing literature, the current dissertation was one of the only 
studies to investigate mechanisms of binge withdrawal-induced hyperalgesia in humans.  
Importantly, we used a mixed between- (Group: history of moderate drinking, history of 
binge drinking) and within- (State: abstain, withdrawal) subjects design to reduce 
individual variability in order to study two objectives.  The first objective was whether 
young adults with a history of binge drinking showed greater pain sensitivity during 
withdrawal on measures of mechanical muscle pain sensitivity, neurogenic 
inflammation, and on a measure of central sensitization – cutaneous thermal temporal 
summation of second pain (between-subject comparison).  Additionally, we compared 
binge and moderate drinkers during withdrawal from a naturally occurring drinking 
episode to their baseline during a period of abstinence (within-subject comparison).  As 
part of this first objective, the present study was also the first to examine whether binge 
drinking altered a thermal measure of pain sensitivity that is thought to reflect the 
underlying process of central sensitization.  Based on prior studies observing effects on 
thermal pain, we used measures of cutaneous thermal sensitivity, including a measure of 
central sensitization – cutaneous thermal temporal summation of second pain.  The 
second objective was to determine whether this binge withdrawal-induced hyperalgesia 
was moderated by circulating levels of epinephrine and IL-6.  Included in the second 
objective, this was also the first study of binge withdrawal-induced hyperalgesia in 
13 
humans to investigate the role of the pro-inflammatory cytokine, IL-6, which has been 
implicated in models of muscle hyperalgesia.
24
  Previous studies have not measured
differences in influential variables related to binge drinking.  Since women may report 
greater experimental pain,
8
 may be more sensitive to the neurological effects of
alcohol,
45,102,105
 and show greater alcohol withdrawal-induced hyperalgesia in an animal
model,
23
 we investigated gender differences in alcohol withdrawal-induced pain.  This
study included secondary analyses of whether pain sensitivity differs by gender.  We 
also investigated differences in adversity, which may be related to binge drinking (e.g., 
those with a stressful past may be more likely to binge drink)
29,76
 and has been shown to
induce a state of mechanical hyperalgesia similar to the alcohol withdrawal-induced 
hyperalgesia
53,54
 as well as including body mass index, which affects the metabolization
of alcohol.  Binge drinkers may also cope differently with stress than moderate drinkers, 
which may lead to more substance use in the early stages of alcohol use disorders.  
Therefore, our study included a measure of coping.
18
This study was designed to test the following hypotheses: that individuals with a 
history of binge drinking will have greater pressure pain sensitivity, neurogenic 
inflammation, and enhanced central sensitization than individuals with a history of 
moderate drinking (objective 1).  In addition, heightened sensitivity and inflammation 
will be moderated by greater baseline epinephrine and IL-6 (objective 2).  These effects 
were hypothesized to be exaggerated by withdrawal. 
14 
METHODS 
The Texas A&M University IRB approved the study and informed consent was 
obtained from all participants. 
Recruitment 
Participants were recruited from spring 2017 to spring 2018.  Individuals were 
eligible if they were healthy, between 18 to 30 years old, and English speaking.  
Individuals were excluded if they endorsed having a chronic pain condition, current use 
of any psychoactive or prescription drugs (excluding contraceptives), a history of 
vasovagal syncope (i.e., fainting), a phobia that would prevent blood draws (e.g., needle 
or blood phobias), skin condition or injury on the lower legs and feet, or chili pepper 
allergy.  At the beginning of each visit, participants were excluded if they had systolic 
blood pressure below 90 or above 160, acute illness, had any dental work within 24 
hours, had 6 or fewer hours of sleep the previous night, had food within 1 hour, or 
brushed their teeth within 30 minutes. 
Potential participants gave their informed consent for screening and completed 
an online screening questionnaire through Qualtrics.com assessing health status and 
drinking history.  Two questionnaires evaluated drinking patterns to classify participants 
as binge or moderate drinkers.  A subset of the health status questionnaire consisted of 
questions asking for the amount participants typically drink and the length of time they 
typically drink.  The second questionnaire, the Daily Drinking Questionnaire (DDQ)
20
15 
asked participants to report the number of drinks consumed during each day of the week 
for their typical and heavy weeks as well as how long they typically drink during those 
days.  Group classification from these questionnaires using the responses with the most 
alcohol consumed was based on National Institute of Alcohol Abuse and Alcoholism 
criteria with individuals reporting 4 (women) or 5 (men) standard drinks every two or 
fewer hour period classified as binge drinkers
71
 and individuals reporting consumption
less than 4 (women) or 5 (men) standard drinks per episode classified as moderate 
drinkers.  In our previous study, there was no difference in mechanical muscle 
hyperalgesia or epinephrine between moderate drinkers and individuals with no history 
of alcohol use.  Therefore, the current study did not include a control group with no 
history of drinking.   
The mixed between-within-subjects design was devised using a recruitment 
procedure and naturally occurring alcohol use similar to our previous study that showed 
exaggerated mechanical muscle hyperalgesia in binge drinkers during withdrawal.
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Due to ethical concerns, participants were not given directions about drinking prior to 
signing up for their first session, however they knew one session would be during the 
withdrawal state and the second visit would be during the abstinence state.  The order 
was determined by the state the participant was in during his/her first session.  Similar to 
our previous study there was a lower recruitment rate of binge drinkers and unexpectedly 
most participants in both groups were in the abstinence state during their first session.  
To improve recruitment of binge drinkers and to increase the proportion of participants 
in withdrawal during the first test session, we modified our recruitment procedures to 
16 
ensure participants would be in the withdrawal state during their first session, but this led 
to a marked reduction in participant recruitment (see Figure 2 for participant flowchart).  
Based on these recruitment and ethical concerns, my dissertation focuses on participants 
who were tested during the abstinence state during session 1 and during the withdrawal 
state during session 2.  According to the power analysis below, we were sufficiently 
powered to test muscle mechanical pain sensitivity. 
Prior to each laboratory visit, individuals were instructed to not take allergy or 
pain medications within 3 days, no dental work within 24 hours, no caffeine within 8 
hours, no exercise that morning, no food within 1 hour, and no brushing of teeth within 
30 minutes.  In addition, individuals needed to have 6 hours of sleep the night before.  
Alcohol consumption was not mentioned to ensure individuals could naturally consume 
alcohol before the first visit. 
Participants can be recontacted in the future to assess the occurrence of chronic 
pain conditions. 
17 
Figure 2.  Flowchart for participants through study. 
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Measures 
The following questionnaires were administered to screen individuals for study 
eligibility.   
The pre-existing health conditions questionnaire is an in-house questionnaire 
with fourteen yes/no items assessing the occurrence of chronic health problems 
including circulatory problems, neurological disorders, numbness in extremities, 
fainting, and phobias. 
The health status questionnaire is an in-house questionnaire consisting of 21 
items assessing current health behaviors including alcohol, nicotine, and caffeine 
histories and use.  Two questions were used to categorize individuals into binge and 
moderate groups, “How many drinks do you usually have on a single occasion?” with a 
free-response answer and “Estimate the number of hours you usually spend drinking” 
with a categorical response. 
 For individuals who self-identified as being a current drinker, categorization for 
drinking was also determined using the Daily Drinking Questionnaire-Revised.
20
  This
questionnaire asked participants to report the standard number of drinks and hours spent 
drinking during typical and heavy weeks in the previous 30 days. 
State characteristics 
Demographics regarding age, sex, and ethnicity were assessed.  Socioeconomic 
status was measured using a battery of questions on the level of parental education and 
employment, family income, household size, current address, and recent parent 
employment. 
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The Early Trauma Inventory Self-Report - Short Form is a questionnaire that 
assesses the self-reported occurrence (yes, no) of 27 adverse events before the age of 
18.
16
  These events fall under general abuse (11 items; Cronbach’s α = .74), physical 
abuse (5 items; Cronbach’s α = .86), emotional abuse (5 items; Cronbach’s α = .92), and 
sexual abuse (6 items; Cronbach’s α = .92).  Additional questions were added regarding 
the age of the first occurrence of a reported adverse event, the number of times it 
occurred, and the effect the events had on the individual at the time it occurred and 
currently.  This questionnaire was added for secondary analyses to investigate a stress-
induced hyperalgesia believed to occur by similar mechanisms as alcohol withdrawal-
induced hyperalgesia.
53,54
The Perceived Stress Scale consists of 10 items used to assess perceived life 
stress in the previous month (Cronbach’s α = .84 - .86).19  The scale ranges from 0
(Never) to 4 (Very Often).  Four items were reverse coded.  Scores were summed so a 
higher score indicates greater perceived stress. 
The Center for Epidemiologic Studies Depression scale is a 20 item scale 
assessing depressive symptoms during the previous week (Cronbach’s α = .85 - .90).78
The scale ranges from 0 (Rarely or none of the time [less than 1 day]) to 3 (Most or all 
of the time (5-7 days)] with scores summed for a total range between 0 and 60.  Four 
items were reverse coded.  Higher scores indicate greater symptoms of depression. 
The Brief COPE is a 28 item measure used to assess 14 types of situational 
responses to a stressor.
18
  Each subscale consists of two items with each item scored on a
0 (I haven’t been doing this at all) to 3 (I’ve been doing this a lot) range (Cronbach’s α = 
20 
0.50 - 0.90).  Scores were summed with higher scores indicating greater reported use of 
the given coping style. 
Alcohol characterization 
Alcohol questionnaires were used to characterize participants and the role of 
positive intoxication and negative withdrawal symptoms.  Questionnaires assessing the 
state effects of alcohol were administered at the end of each visit to measure the effect of 
consumed alcohol compared to no alcohol consumption. 
State alcohol-related questionnaires 
The Acute Hangover Scale is a 9 item measure used to calculate nine current 
hangover symptoms (Cronbach’s α = .84).83  Average scores for thirsty, tired, headache,
dizziness, loss of appetite, stomachache, nausea, and heart racing were computed on a 0 
(None) to 7 (Incapacitating) scale.  Average scores ranged from 0.6 (SD = 0.4) the 
morning after placebo (nonalcoholic beer or soda and tonic water with a few drops of 
alcohol) and 1.4 (SD = 0.9) the morning after drinking alcohol to 0.10 g% breath alcohol 
content.
83
  No items were reverse coded.  A higher score indicates greater perceived
withdrawal symptoms. 
The Alcohol Craving Questionnaire-Short Form-Revised is a self-report measure 
evaluating levels of alcohol craving.
90
  Scores were calculated for three subscales:
emotionality (Cronbach’s α = .86), purposefulness (Cronbach’s α = .77), compulsivity 
(Cronbach’s α = .79), and expectancy (Cronbach’s α = .77).  Each item was reported on 
a 1 (strongly disagree) to 7 (strongly agree) range.  Eight items were reverse coded and 
scores were summed so higher scores indicate greater craving. 
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The Craving Typology Questionnaire is a 20 item questionnaire assessing three 
dimensions of craving
67
 that more closely assess the pain and alcohol dependence model
described previously.
28,38
  Scores were calculated for three subscales: relief craving (5
items, Cronbach’s α = 0.81), obsessive craving (8 items, Cronbach’s α = 0.88), and 
reward craving (7 items, Cronbach’s α = 0.83).  Each item was reported on a 1 
(completely false) to 5 (completely true) range.  No items were reverse coded.  A higher 
score indicates greater craving. 
The Biphasic Alcohol Effects Scale (BAES) is a 14 item self-report questionnaire 
to determine the subjective acute stimulant (7 items; Cronbach’s α = 0.94) and sedative 
(7 items; Cronbach’s α = 0.87) effects of alcohol.66  Each item was reported on a 0 (not
at all) to 10 (extremely) range.  No items were reverse coded.  Scores for the stimulant 
and sedative subscales were summed and ranged from 0 to 70 with higher scores 
indicating greater stimulant and sedative effects of alcohol, respectively. 
Tonic alcohol-related questionnaires 
The drinking quantity/frequency index is an in-house questionnaire composed of 
a three item questionnaire gauging typical drinking during the weekdays and weekends 
during the past month. 
The Hangover Symptoms Scale is a 13 item measure assessing the frequency of 
13 hangover symptoms in the past 12 months (Cronbach’s α = 0.84).91  Each item was
scored on a 0 (Never) to 4 (Every time) range.  Responses were dichotomized to reflect 
the presence (1-4) or absence (0) of the symptom and then summed.  Total scores ranged 
from 0 to 13 with a higher score indicating more hangover symptoms. 
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The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item measure 
used to assess drinking behaviors and alcohol-related problems.
40
  Each item is scored
on a 0 to 4 range with different anchors for individual questions.  No items were reverse 
coded.  Scores were summed and range from 0 to 40 with scores of 8 or greater 
indicating harmful drinking. 
The Urgency, Premeditation, Perseverance, and Sensation (UPPS) Seeking 
Impulsive Behaviour Scale is a 45 item measure used to assess four dimensions of 
impulsivity.
104
  The current study assessed sensation seeking using the 12 items of the
sensation seeking subscale (Cronbach’s α = 0.85).  Each item was scored on a 1 
(Strongly Agree) to 4 (Disagree Strongly).  No items were reverse coded.  Scores were 
summed with higher levels indicating more sensation seeking (i.e., more impulsive) 
behavior. 
Responses to pain 
The Spielberger State-Trait Anxiety Inventory-6 (STAI) is a 6 item short form 
measure used to assess levels of state anxiety (Cronbach’s α = 0.82).65  Each item was
scored on a 1 (Not at all) to 4 (Very much).  Three items were reverse coded and scores 
were summed with higher scores indicating greater anxiety. 
The Positive and Negative Affect Schedule (PANAS) is a 20 item measure used 
to assess current positive (Cronbach’s α = .86) and negative affective states (Cronbach’s 
α = .87).103  No items were reverse coded.  Each item is scored on a 0 (Very Slightly) to 4
(Extremely) range and scores were summed with higher scores indicating greater 
positive or negative affect. 
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The Self-Assessment Manikin (SAM) is a 3 item measure assessing current 
valence, arousal, and dominance dimensions of affect.
14
  Valence is scored on a 1
(Happy) to 9 (Unhappy) range, arousal is scored on a 1 (Calm) to 9 (Excited), and 
dominance is scored on a 1 (Feeling being controlled) to 9 (Feeling in control).  Higher 
scores indicate more negative affect (valence), greater arousal (arousal), and greater 
control (dominance). 
Two visual analog scales (VAS) each consisting of a 10 centimeter line were 
displayed on a computer monitor and were used to measure the intensity and 
unpleasantness of capsaicin-induced spontaneous pain.
77
  The horizontal lines were
labeled with the anchors 0 (no pain) to 100 (most intense pain imaginable) for intensity 
and 0 (no pain) to 100 (most unpleasant pain imaginable) for unpleasantness.  Higher 
scores indicate more intense or unpleasant aspects of pain, respectively. 
Quantitative Sensory Testing 
All quantitative sensory testing (QST) was conducted in a sound-attenuated and 
temperature controlled room (22-28°C).  The dominant arm was preferred for blood 
draws but the non-dominant arm would be used if a venipuncture site could not be found 
on the dominant arm.  To prevent carry-over from the blood draw, all QST, with the 
exception of the first three steps of the temporal summation of second pain procedure, 
was conducted on the side of the body contralateral to the blood draw. 
Pressure pain threshold 
The muscle pressure pain threshold was measured using a modified version of 
the German Research Network on Neuropathic Pain protocol
84
 and a handheld algometer
24 
(FPX 50, Wagner Instrument, Connecticut, USA).  Three threshold tests with 15 second 
intervals were administered on the muscle between the toes, approximately one inch 
from the edge.  The first stimulation was between the first (medial) and second toes, the 
second between the second administered third toes, and the third between the third and 
fourth toes.  The experimenter put the 1cm
2
 diameter rubber tip on the skin at a 90°
angle and increased the pressure by 50kPa/s (~0.5kg/cm
2
s) until the participant reported
pain at which point, the algometer was removed and the force recorded. 
Participants listened to an audio track explaining the threshold test and were then 
read the following verbal script: “Now I will put this tip on your foot and slowly increase 
the pressure.  Please look at the black dot in front of you and say “STOP” as soon as the 
stimulus becomes painful.  Please do not respond when you feel a lot of pressure or 
when you feel a lot of pain, but just when you start to feel pain.  Do you have any 
questions?”  Prior to each test, participants were reminded to “Please say stop as soon 
as you start to feel pain.  Do you have any questions?” 
The method used in animal studies of alcohol withdrawal-induced muscle 
mechanical hyperalgesia mainly used the Randall-Selitto method to apply pressure to the 
muscle
3,23,25,27,79
.  Similarly, we used a handheld algometer to apply pressure to the foot
muscles to assess pressure pain threshold.  Our procedure in humans likely stimulated a 
proportionally equivalent spatial area of nociceptors as the Randall-Selitto method in 
animal models.  Due to the similar methodologies and nociceptors stimulated, we use 
mechanical and pressure interchangeably. 
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Capsaicin 
Capsaicin-induced spontaneous pain was assessed over 45 minutes and flare 
were assessed using 0.3mL of a 0.10% topical capsaicin solution (Zostrix, Akorn 
Consumer Health, Ann Arbor, MI, USA).
85
  First, a 16mm diameter circle was drawn on
the volar aspect of the forearm contralateral to the blood draw.  Care was taken to ensure 
visible veins or arteries were not inside the circle.  Participants were then trained on how 
to rate the intensity and unpleasantness of their pain on a visual analog scale (VAS).  
After this, participants were told about the procedure after which a thin layer of Vaseline 
was applied around the circumference of the circle to prevent the spread of capsaicin 
solution.  The capsaicin solution was topically applied and covered with a medical 
dressing (Tegaderm Film, 3M, St. Paul, Minnesota, USA).  Skin temperature was 
measured at two opposing points around the medical dressing and at one point near the 
medial aspect of the wrist.  Room temperature was also measured.  Participants then 
rated the intensity and unpleasantness of their pain on the VAS and affect on the SAM 
every 3 minutes for 45 minutes.  Ratings were prompted by a mild auditory cue.  At the 
end of 45 minutes, skin and room temperatures were measured, the bandage quickly 
removed, and capsaicin wiped off.  Following flare assessment, residual capsaicin was 
dissolved and removed using vegetable oil. 
Neurogenic flare was assessed using a laser doppler imager (MoorLDI2-IR, 
Moor Instruments Ltd., London, UK).  The imager was placed approximately 50cm from 
the forearm and the resulting scan (256x256 pixels; spatial resolution of 4ms/pixel) took 
approximately 5 minutes.  Area of flare (cm
2
) was quantified from the image using Moor
26 
LDI image review 5.3 software.  The size of flare was calculated as the area of 
hyperemia (>300pfu).
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Temporal summation of second pain 
Cutaneous temporal summation of second pain (TSSP) was assessed using a 
four-step process using a 3 x 3cm
2
 Peltier thermode (Medoc Advanced Medical Systems,
Ramat Yishai, Israel).  To reduce the potential for sensitization, during the first three 
steps participants switched hands for each trial, beginning with the hand ipsilateral to the 
blood draw.  Only the four test trains occurred on the same (contralateral to blood draw) 
hand.  First, to acclimate participants to the thermal stimuli, participants were 
administered three thermal pulses lasting 2 seconds each at 45°C, 46°C, and 47°C
12,13
 at
one minute intervals.  Second, sensitivity tests using a modified staircase method were 
used to individualize the temperature needed to induce moderate pain ratings of 50 ± 10 
NPR.
12,13,94
  Pilot testing suggested using fixed step sizes of 1°C would allow for quicker
discrimination between pain intensities.  To determine this temperature, a maximum of 6 
trains of 4 heat pulses at 0.33Hz were administered to the palmar thenar eminence.  All 
trains of pulses began at a baseline of 38°C and, for the initial sensitivity test, increased 
to a peak temperature of 47°C.  The target temperature for the following trials moved in 
1°C increments until the participant rated 50±10 NPR.  To ensure the specificity of the 
temperature, one more step was administered beyond the 50±10 NPR temperature 
followed by a 1°C step prior to the 50±10 NPR temperature.  To control for differences 
in pain sensitivity during each drinking state, if the temperature was individualized for a 
participant during at least one state, the temporal summation of second pain procedure 
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was conducted during the other state even if the individualized temperature was outside 
the 50±10 NPR range during that other state.  This may result in a pain rating and 
individualized temperature falling outside of 50±10 for some participants.  Third, a 3 
minute video clip created by the experimenter was shown to the participant explaining 
the second pain (referred to as “late sensation” so as to not bias individuals to being 
scared of the sensation) as opposed to the first pain (referred to as “early sensation”).  
Four questions were asked to the participant to identify any misunderstandings of the 
second pain.  Then, trains of 6 stimuli at the individualized temperature were delivered 
in one minute intervals on alternating hands.  Participants were told to recognize the late 
sensation and no ratings were made.  For the last train, participants clicked a button on a 
wireless keyboard when they feel the late sensation.  This, in combination with 
measuring the length of the arm measured at the beginning of the first visit allows for an 
approximate estimate of the involvement of C-fibers.
93
  Fourth, during TSSP testing,
four test trains of 10 heat pulses each at 0.33Hz were administered to the hand 
contralateral to the blood draw.  Three minute breaks were administered between trains.  
Participants were asked to rate their pain intensity after each heat pulse and 
aftersensations at 15 seconds, 30 seconds, and 45 seconds, prompted by audio cues from 
a laptop. 
Physiological Measures 
Physiological responses were recorded using a BIOPAC MP150 data acquisition 
system (BIOPAC Systems, Inc., Goleta, CA, USA) interfacing with AcqKnowledge 4.2 
software.  Data was sampled at 1000Hz.  Respiration was measured using a RSP100C 
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amplifier with a respiration transducer to measure thoracic and abdominal respiration.  
Heart rate was recorded using a ECG100C amplifier with two Ag-AgCl electrodes 
positioned in a modified lead-2 placement.  Heart rate is expressed in beats per minute 
(BPM) as well as interbeat interval (IBI), the latter of which is linearly related to 
parasympathetic nervous system activity.
52
  Skin conductance was recorded using a
GSR100C amplifier with two Ag-AgCl electrodes attached to the volar aspect of the 
medial phalanx of the index and middle finger of the hand contralateral to the blood 
draw.  Skin conductance and respiration data were analyzed offline using 
AcqKnowledge 4.2 software (BIOPAC Systems, Inc., Goleta, CA) and heart rate data 
were analyzed offline using EDF Browser v1.63 software (Teunis van Beelen).  Data 
were filtered using band-pass finite impulse response (FIR) filters for respiration (0.05 - 
1Hz),
11,111,114
 heart rate (0.5 - 35Hz, 8,000 coefficients),
10,111,114
 and skin conductance
(1Hz FIR low pass filter).
111,114
Enzyme-Linked Immunosorbent Assay (ELISA) 
All plasma samples were thawed once prior to analyses and standards, controls, 
and samples were analyzed in duplicate according to the manufacturer’s manual.  
Epinephrine kits were purchased from Abnova (Taipei, Taiwan, Catalog number 
KA1877) and IL-6 kits and controls were purchased from R&D Systems (Minneapolis, 
MN, Catalog number D6050 [ELISA kits] and QC01-1 [controls]).  Plate-to-plate 
variability was reduced by randomly assigning all samples in duplicate for a participant 
to a kit with approximately equal numbers of each group assigned to each plate.  All 
plasma samples were thawed on ice and extraction and acylation were conducted at 
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room temperature.  Epinephrine and IL-6 analyses were conducted according to 
manufacturer’s protocols.  Absorbance values for epinephrine and optical density values 
for IL-6 were used to construct standard curves for determination of concentrations of 
epinephrine and IL-6 in plasma from participants via AssayZap software (Biosoft, 
Cambridge, UK).  Samples from excluded participants were included when determining 
the standard curve in order to create a pool of sample data.  During epinephrine 
extraction, plate 1 incubated in assay buffer and extraction buffer an additional 20 
minutes and plate 2 incubated in acylation buffer and acylation reagent an additional 20 
minutes.  All plates were read using a Bio Rad Model 680 Microplate Reader (Bio Rad 
Laboratories, Inc., Hercules, California). 
Procedures 
Questionnaire data was collected using Qualtrics online survey software.  All 
pain sensitivity tests were conducted by the author and both the author and trained 
undergraduates collected baseline blood pressure and breathalyzer data.  The author was 
blind to the participant’s group.  All correspondence regarding group categorization and 
the visit condition was made by a trained undergraduate who did not do pain sensitivity 
tests. 
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Figure 3.  Timeline of study procedures.  Individuals interested in participating were prescreened. 
Eligible participants were invited and took part in the Abstain and Withdrawal state visits. 
The protocols for the two visits were largely equivalent with the exception of 
informed consent on the first visit and debriefing and compensation at the end of the 
second visit (see Figure 2 for study timeline).  All state visits took place between 
12:00pm and 7:00pm to reduce the effect of diurnal cortisol variability on pain and stress 
hormones.  To improve recruitment, participants arrived at a predetermined location: 
either the laboratory or the local student health center for each visit and were asked 
questions to verify their eligibility.  They were then provided with written and oral 
informed consent information.  Following informed consent, their blood pressure was 
measured and 14mL of blood was drawn, with their dominant arm preferred, by a trained 
phlebotomist (the author or student health center phlebotomist).  After the blood draw, 
for participants starting in the student health center, they moved to the laboratory and 
were asked for the intensity and unpleasantness of their pain to the blood draw.  
Participants already in the laboratory were asked the same questions related to the blood 
draw.  A saliva sample was then taken.  Participants moved to the experiment room and 
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had physiological sensors applied to measure respiration, heart rate, and skin 
conductance.  Following this, participants filled out baseline questionnaires and took 
online training for the Self-Assessment Manikin.  Once the questionnaires were 
completed, participants were asked to remove the shoe and sock contralateral to the 
blood draw, after which 5 minutes of physiological data were collected.  After five 
minutes, the pressure pain threshold test was conducted, after which blood pressure was 
measured on their left arm and participants put their shoe and sock back on.  After 
another 5 minutes of physiological data collection, a circle was drawn on the volar 
aspect of the forearm contralateral to the blood draw.  The experimenter was careful to 
avoid visible blood vessels when possible.  Participants were then trained on how to rate 
the intensity and unpleasantness of their pain on the visual analog scale and practiced 
making ratings.  Once the participant was comfortable rating their pain, a thin layer of 
Vaseline was placed around the perimeter of the circle and 0.3mL of a mild topical 
capsaicin solution was applied to the skin (Zostrix) and covered with a transparent 
medical bandage (Tegaderm, 3M).  After the capsaicin was applied, participants rated 
the intensity and unpleasantness of their capsaicin-induced pain on the VAS as well as 
their valence, affect, and dominance on the SAM every 3 minutes for 45 minutes.  
During this time, the participant was alone in the experiment room and was prompted to 
make their ratings by a mild audio cue.  Following 45 minutes, the capsaicin was 
removed and participants moved to the next room for the flare measurement.  After the 
flare measurement, oil was applied to the capsaicin site to dissolve and remove capsaicin 
any remaining capsaicin.  Participants moved back to the experiment for the temporal 
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summation of second pain procedure.  Following the temporal summation procedure, at 
the beginning of three minutes of physiological data collection, participants were told to 
remove the shoe and sock on the foot contralateral to the blood draw.  After the three 
minutes, a second pressure pain threshold was administered followed by exit 
questionnaires. 
Sample Size 
GPower 3.1.9.2 was used to calculate a priori sample size for mixed ANOVAs.  
A medium effect size (f = 0.25) calculated using epinephrine results from a previous 
study,
114
 for two visits per person in each group, with an alpha of .05, 80% power, a 0.5
correlation among repeated measures, and a nonsphericity correction of 1 were entered.  
The results indicated a minimum total sample size of 34 (n = 17 per group) was needed. 
A second power analysis with a medium effect size (f = 0.25) was calculated 
using muscle mechanical hyperalgesia results from a previous study.
114
  For two visits
per person in each group, with an alpha of .05, 80% power, a 0.5 correlation among 
repeated measures, and a nonsphericity correction of 1 suggested a total sample size of 
16 (n = 8 per group) was needed. 
Statistical Analysis 
Statistical assumptions were examined.  Normality was evaluated using the 
Shapiro-Wilk’s test.  Homogeneity of variance was evaluated using Levene’s test.  
Variables violating normality or variance were transformed according to standard 
conventions.  Outliers were detected if they were outside the mean ± 3 SD.  If outliers 
were detected, they were removed from analyses only if there was sufficient reason for 
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being an outlier.  For repeated measures analyses with more than two levels for a 
repeated measure, the sphericity assumption was tested using Mauchly’s test and 
deviations from sphericity were corrected using Greenhouse-Geisser if the estimated 
epsilon (ε) was less than 0.75 or Huynh-Feldt if the estimated epsilon was greater than 
0.75.  The first hypothesis regarding greater pain and neurogenic inflammation in binge 
drinkers and those in withdrawal was tested using Mixed ANOVAs for pressure pain 
threshold and flare and a Mixed RM ANOVA for temporal summation of second pain.  
The second hypothesis that pain and inflammation is related to greater baseline 
epinephrine will be tested using a Mixed ANOVA and correlations.  Effects of gender 
were analyzed by running separate analyses on women and men. 
Missing Data 
No missing data values were included in pain sensitivity and 
psychophysiological analyses.  All questionnaires were completed with the exception of 
one participant’s CES-D during the abstain visit.  To ensure the data from the same 
participants used for the pain sensitivity analyses were included in every analysis, 
individuals with missing data in the pain sensitivity tests were excluded and pairwise 
deletion was used for remaining analyses.  Individuals with missing or unrecoverable 
heart rate, respiration, and skin conductance data due to equipment malfunction or 
missing questionnaire and affect data were analyzed using pairwise deletion. 
Following data collection, participants were excluded from analyses if the 
participant did not follow directions regarding drinking prior to a visit, if they were a 
heavy drinker (i.e., consumed binge levels of alcohol at a rate below binge drinking [2 
34 
drinks/hour for women, 2.5/hour for men]), if they did not report P50 for both visits, if 
different pain sensitivity methods were piloted on the participant, or TSSP was not 




In total, 29 participants completed the study (see Figure 2 for participant flow 
chart). 
Table 1 shows the demographic and coping data for the sample.  Moderate and 
binge drinkers did not differ in age, gender, ethnicity, cigarette use, and number of 
adverse life event types experienced (sum of general trauma, physical abuse, emotional 
abuse, and sexual abuse), all ps > .17.  Binge drinkers did endorse use of more 
instrumental support, t(27) = 2.19, p = .038, and behavioral disengagement, χ2(1) = 5.83,
p = .008, when coping with stress. 
Table 1. Baseline Demographic and Psychological Characteristics. 
Moderate Drinkers 
(n = 13) 
Binge Drinkers 
(n = 16) 
Characteristic M (SD) M (SD) t p 
Age 21.23 (2.77) 22.00 (3.50) 0.64 .53 
Gender (% Female)† 56.25% 38.46% 0.91 .34 
Ethnicity (% Caucasian)† 50.00% 53.85% 3.29 .51 
Cigarette use (%) ‡ 92.31% 75% 1.00 .34 
Adversity (number of event types) 3.92 (2.50) 2.69 (2.21) -1.41 .17 
Coping 
Active Coping 6.15 (1.28) 5.63 (1.26) -1.12 .27 
Planning‡ 6.00 (1.41) 6.06 (1.24) 6.00 .47 
Positive Reframing 5.08 (1.61) 5.56 (1.67) 0.79 .44 
Acceptance‡ 5.31 (1.38) 5.50 (1.03) 6.00 .57 
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Table 1. Continued. 
Humor 4.23 (1.48) 5.31 (1.78) 1.75 .09 
Religion‡ 4.15 (1.99) 3.56 (1.97) 3.00 .72 
Using Emotional Support 4.23 (1.54) 4.88 (1.82) 1.02 .32 




 2.19 .04* 
Self-Distraction 5.69 (1.11) 5.44 (1.15) -0.60 .55 
Denial‡ 2.46 (1.13) 2.63 (0.96) 2.00 .45 
Venting‡ 4.08 (0.95) 4.40 (1.45) 4.00 .48 
Substance Use‡ 2.69 (1.25) 3.31 (1.49) 2.00 .26 
Behavioral Disengagement‡ 2.31 (1.11)a 3.00 (1.21)b 2.00 <.01** 
Self-Blame‡ 4.23 (1.48) 4.94 (1.53) 5.00 .09 
Note. Independent samples t-tests were performed unless otherwise indicated. †chi-square test was 
performed with sample means and standard deviations reported. ‡Kruskal-Wallis test was performed with 
sample means, standard deviations, and medians reported. 
*p < .05. **p < .01.
Table 2 shows alcohol use and craving characteristics.  Binge drinkers reported 
more alcohol use disorder symptoms, t(22.05) = 2.91, p = .008, a greater number of 
standard drinks prior to the withdrawal state, χ2(1) = 5.57, p = .008, a greater number of
drinks typically consumed, χ2(1) = 19.45, p < .001, greater typical hangover symptoms,
t(27) = 2.47, p = .02, and a greater frequency of consuming 4-5 drinks for women and 
men, respectively, χ2(1) = 14.95, p < .001.  Notably, despite our participants drinking
more prior to withdrawal and reporting typically greater hangover symptoms, they did 
not differ from moderate drinkers in reported acute hangover symptoms, all ps > .3. 
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Table 2. Alcohol Use and Craving Characteristics. 
Moderate Drinkers 
(n = 13) 
Binge Drinkers 
(n = 16) 
Abstain Withdrawal Abstain Withdrawal 
Characteristic M (SD) M (SD) M (SD) M (SD) t p 
BMI 23.03 (4.05) 24.66 (4.24) 1.05 .30 
Age of first drink 
(years) 
18.69 (1.75) 18.03 (1.97) -0.94 .35 






















UPPS - Sensation 
Seeking 






Number of drinks 







AHS 0.70 (0.14) 0.77 (0.13) 0.94 (0.13) 0.85 (0.12) 0.77 .39 
ACQ 33.85 (3.52) 30.54 (2.70) 38.50 (3.17) 37.25 (2.43) 0.34 .56 
   Compulsivity 5.62 (4.61) 4.54 (2.30) 5.44 (2.58) 6.06 (3.32) 2.24 .15 
   Expectancy 9.08 (1.26) 7.69 (1.02) 10.94 (1.14) 10.50 (0.92) 0.44 .52 
   Purposefulness 10.15 (1.05) 11.23 (0.93) 13.38 (0.95) 12.00 (0.84) 3.52 .07 
   Emotionality 9.00 (4.34) 7.08 (4.50) 8.50 (3.72) 8.69 (4.38) 2.02 .17 
CTQ 
Reward 15.69 (3.07) 15.77 (2.52) 18.56 (4.59) 21.00 (4.34) 4.98 .03* 
Relief 10.23 (1.09) 10.85 (1.05) 11.94 (0.99) 12.38 (0.94) 0.04 .85 
Obsessive Craving 9.77 (2.74) 9.69 (3.01) 10.88 (3.83) 10.75 (3.94) 0.00 .95 
BAES 









    Sedative 33.92 (3.51) 31.23 (4.33) 42.19 (3.16) 39.94 (3.91) 0.01 .91 
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Table 2. Continued. 
Note. Independent samples t-tests and mixed ANOVAs were performed unless otherwise indicated. 
‡Kruskal-Wallis test was performed with sample means, standard deviations, and medians reported. 
Superscript letters indicate significant differences between visits or groups. UPPS - Sensation Seeking = 
UPPS Impulsive Behavior Scale - Sensation Seeking subscale; AUDIT = Alcohol Use Disorder 
Identification Test; AHS = Acute Hangover Scale; ACQ = Alcohol Craving Questionnaire; CTQ = 
Craving Typology Questionnaire; BAES = Biphasic Alcohol Effects Scale. 
*p < .05. **p < .01.
Table 3 shows psychological and physiological characteristics at the beginning of 
each drinking state visit.  For perceived stress, we found a main effect of group, F(1, 26) 
= 11.95, p = .002, with the binge group reporting more stress at the start of each state.  
We also found main effects of drinking state for state anxiety, F(1, 26) = 7.92, p = .009, 
negative affect, F(1, 26) = 7.46, p = .011, and perceived dominance, F(1, 24) = 5.81, p = 
.024, indicating participants at the start of the withdrawal state felt less anxious, less 
negative, and more dominant.  Interestingly, we also found main effects of state for heart 
rate in beats per minute, F(1, 27) = 5.37, p = .028, and interbeat interval, F(1, 27) = 7.98, 
p = .009, as well as respiration rate, F(1, 24) = 5.46, p = .028, with participants at the 
start of the withdrawal state having a faster heart rate and a shorter interbeat interval 
along with a faster respiration rate.  While there was a trend for a State x Group 
interaction for positive affect, F(1, 26) = 3.65, p = .067, with the binge group reporting 
less positive affect during withdrawal, there were no differences between state, group, or 
interaction for depressive symptoms, positive affect, valence, arousal, and skin 
conductance level, all ps > .07. 
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Table 3. Baseline Psychological and Physiological Characteristics. 
Moderate Drinkers 
(n = 13) 
Binge Drinkers 
(n = 16) 
Abstain Withdrawal Abstain Withdrawal 


















 0.88 .36 
CESD 10.82 (2.48) 8.55 (2.18) 15.50 (2.06) 12.88 (1.81) 0.02 .89 
PANAS 
Positive affect 28.50 (2.56) 28.42 (2.45) 27.44 (2.22) 22.81 (2.12) 3.65 .07 








 2.20 .15 
SAM 
Valence 6.46 (0.31) 6.82 (0.42) 6.27 (0.27) 6.2 (0.36) 1.03 .32 









 0.00 .96 








 0.78 .39 








 0.71 .41 
Skin conductance 
level (sqrtμS) 










 1.40 .25 
Note. Mixed ANOVAs were performed. Superscript letters indicate significant differences between visits 
or groups. PSS = Perceived Stress Scale; STAI = State Trait Anxiety Inventory; CESD = Center for 
Epidemiological Studies - Depression; PANAS = Positive And Negative Affect Schedule; SAM = Self-
Assessment Manikin; BPM = beats per minute; IBI ms= interbeat interval in milliseconds; sqrtμS = square 
root of microsiemens; BrPM = breaths per minute. 
*p < .05. **p < .01.
Pain Sensitivity 
Muscle pressure pain 
Figure 4 shows pressure pain threshold at the beginning (Fig. 4A) and end (Fig. 
4B) of each state as well as a comparison of tests at the beginning and end (Fig. 4C).  To 
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assess whether our participants with histories of binge drinking and in withdrawal report 
muscle mechanical hyperalgesia similar to previous studies, we measured pressure pain 
threshold at the beginning and end of each state. 
For muscle pressure pain threshold at the beginning of the study (Fig. 4A), we 
found a main effect of state, F(1, 27) = 13.38, p = .001, with a lower threshold (i.e., 
greater pain sensitivity) during withdrawal than abstinence.  This indicates withdrawal-
induced mechanical hyperalgesia.  While there was a trend toward a main effect of 
group, F(1, 24) = 3.36, p = .078, this failed to reach significance.  There was no 
interaction, p = .54.  Muscle pressure pain threshold at the end of each drinking state 
(Fig. 4B), we found no main effects nor interactions, all ps > .10.  When we included 
both assessments in our analysis (Fig. 4C), we found a State x Time interaction, F(1, 27) 
= 4.53, p = .043.  This interaction was driven by participants in withdrawal reporting 
Figure 4.  Pressure pain thresholds at the (A) beginning and (B) end of each drinking state as well as (C) a 
comparison of threshold tests.  Error bars = SEM. * = p < .05.
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consistently lower thresholds while participants in abstinence reporting a higher 
threshold than during withdrawal.  This reduced threshold during withdrawal is likely 
due to sensitization. 
Capsaicin-induced neurogenic inflammation and spontaneous pain 
Figure 5 shows the area (Fig. 5A) and intensity (Fig. 5B) of neurogenic flare.  To 
determine whether a history of binge drinking or withdrawal affect neurogenic 
inflammation, we measured the area and intensity of capsaicin-induced neurogenic flare.  
Mixed between-within subjects ANOVAs on the area and intensity of flare found no 
main effects nor interactions, all ps > .25, suggesting history of alcohol use and 
withdrawal in our sample did not affect the area or intensity of flare. 
Figure 6 shows the ratings of the intensity (Fig. 6A) and unpleasantness (Fig. 6B) 
of capsaicin-induced spontaneous pain.  Mixed between-within-within subjects analyses 
Figure 5.  (A) Area and (B) intensity of capsaicin-induced neurogenic flare.  Error bars = SEM. 
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showed main effects of time for both the intensity, F(1.18, 30.6) = 22.65, p > .001, and 
unpleasantness, F(1.26, 32.85) = 24.32, p < .001, with ratings increasing over time.  No 
other main effects nor interactions were found, all ps > .20.  This suggests the dose of 
capsaicin used was sufficient to induce intense and unpleasant pain. 
Figure 6. Capsaicin-induced (A) intensity and (B) unpleasantness of spontaneous pain during both abstain 
and withdrawal states.  Error bars = SEM. 
Static cutaneous thermal pain and temporal summation of second pain 
We assessed thermal pain and thermal temporal summation of second pain to 
determine if a history of binge drinking and withdraw sensitized the ascending pain 
pathway. 
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Cutaneous thermal pain 
Figure 7 shows participant ratings at 45°C (Fig. 7A), 46°C (Fig. 7B), and 47°C 
(Fig. 7C).  To acclimate participants to the thermal device, we administered standardized 
thermal stimuli 2 seconds in length with each pulse at 45°C, 46°C, and 47°C with an 
interstimulus interval of at least 1 minute.  We found a main effect of state at 45°C, F(1, 
25) = 27.45, p < .001, 46°C, F(1, 25) = 35.69, p < .001, and 47°C, F(1, 25) = 47.44, p <
.001.  At each temperature, participants reported less pain during the withdrawal state 
than the abstain state.  This cutaneous thermal hypoalgesia suggests that while in 
withdrawal, participants were less sensitive to thermal stimuli. 
Figure 7.  Pain ratings to 2 stimuli at (A) 45°C, (B) 46°C, and (C) 47°C.  Error bars = SEM. * = p < .05. 
Prior to cutaneous temporal summation, we individualized the temperature to be 
used during temporal summation to a temperature at which the participant reliably rated 
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their pain to be 50 out of 100 (i.e., P50).  Figure 8 shows the temperature (Fig. 8A) and 
pain ratings (Fig. 8B) for the individualization procedure.  For the temperature, we found 
a main effect of state, F(1, 27) = 12.50, p = .001, with individuals during the withdrawal 
state needing a higher temperature to reach P50 than during the abstain state.  For the 
pain ratings, we found a State x Group interaction, F(1, 27), = 6.61, p = .016, with binge 
drinkers reporting similar pain levels during both states while moderate drinkers reported 
less pain during the withdrawal state.  There was also a main effect of visit, F(1, 27) = 
12.98, p = .001, for pain rating, with the participants in the withdrawal state reporting 
less pain than in the abstain state.  This suggests that participants during the withdrawal 
state needed a higher temperature than during the abstain state to achieve approximately 
equivalent thermal pain ratings.  In addition, drinkers during the withdrawal state, 
particularly moderate drinkers, reported lower pain to the individualized temperature 
than during the abstain state.  These results corroborate the thermal hypoalgesia found 
using the standardized thermal stimuli above. 
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Cutaneous thermal temporal summation of second pain 
Figure 9 shows the pain ratings of the second pain sensation following each of 
the 10 thermal stimulations and three aftersensations at 15 second intervals following 
cessation of the 10th pulse.  During the 10 pulse temporal summation of second pain 
procedure, we found a main effect of pulse, F(1.41, 38.18) = 6.50, p = .008, with pain 
increasing over the course of the pulses.  This suggests that the procedure did induce 
temporal summation.  Over the 10 pulses, we found a visual trend toward binge drinkers 
reporting enhanced temporal summation during both abstinence and withdrawal phases 
compared to moderate drinkers, F(1, 27) = 0.71, p = .406.  Since our data suggests 
sensitization over the first five pulses and based on previous studies supporting 
sensitization over the first 4-6 pulses,
93,113
 we conducted an exploratory analysis of the
Figure 8.  (A) Individualized temperature and (B) pain rating to achieve rating of 50/100 (P50).  
Error bars = SEM. * = p < .05. 
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first five pulses of data.  We found a main effect of pulse, F(1.51, 40.83) = 23.00, p < 
.001, with increasing pain over the course of the first five pulses.  Additionally, we 
found a trend towards a State x Pulse interaction, F(1.90, 51.17) = 3.06, p = .058 with a 
slight linear increase over the five pulses during withdrawal while during abstinence, 
ratings began to plateau after the third pulse.  The visual trend of enhanced temporal 
summation in binge drinkers compared to moderate drinkers was not supported, F(1, 27) 
= 1.42, p = .244. 
Figure 9.  Second pain ratings across 10 thermal heat pulses and subsequent aftersensations.  Sensitization 
is indicated by increasing pain over the ten pulses (pulses indicated by arrows).  Pain threshold is indicated 
by the shaded area.  Error bars = SEM. 
Following cessation of the stimulations, we found a State x Time interaction for 
the aftersensations, F(2, 54) = 3.24, p = .047, (Fig. 10) with pain ratings during the 
withdrawal state decreasing more rapidly during the abstinence state.  There was also a 
main effect of time, F(1.13, 30.56) = 44.38, p < .001, with pain ratings decreasing over 
time.  This further corroborates the thermal hypoalgesia found above. 
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Figure 10.  Aftersensations during abstinence and withdrawal states.  AS15 = Aftersensation at 15 
seconds; AS30 = Aftersensations at 30 seconds; AS45 = Aftersensations at 45 seconds.  Error bars = SEM. 
Role of Epinephrine and IL-6 in Pain Sensitivity 
Due to the undetectable levels of epinephrine and IL-6 across participants, the 
epinephrine and IL-6 data are not presented. 
Differences in Pain Sensitivity Between Genders 
Figure 11 shows mechanical muscle sensitivity (Fig. 11A), P50 temperature (Fig. 
11B), P50 pain rating (Fig. 11C), rating pain aftersensations following temporal 
summation of second pain (Fig. 11D), and neurogenic flare (Fig. 11E) results by gender.  
When analyses were conducted separately in women and men, a main effect of state was 
found for muscle mechanical pain threshold at the beginning of the study in men, F(1, 
13) = 6.62, p = .023, while only a trend was found for women, F(1, 12) = 4.65, p = .052.
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Regarding cutaneous thermal pain sensitivity, men showed main effects of state for the 
P50 temperature, F(1, 13) = 14.55, p = .002, and pain ratings, F(1, 13) = 13.90, p = .003.  
No effect was found in women, all ps > .08.  In addition, for aftersensations following 
cutaneous thermal temporal summation of second pain, men showed a significant State x 
Time interaction, F(2, 26) = 4.72, p = .018 as well as a main effect of time, F(2, 26) = 
20.44, p < .001.  Only a main effect of time was found for women, F(2, 24) = 24.47, p < 
.001.  This suggests that the alcohol withdrawal-induced muscle mechanical 
hyperalgesia and cutaneous thermal hypoalgesia were potentially driven by effects in 
male participants. 
However, for intensity of neurogenic flare, women showed a main effect of state, 
F(1, 12) = 5.75, p = .034, with women during the withdrawal state showing more intense 
flare than when they were in the abstinence state.  No effects were found in men, all ps > 
.34.  No other main effects were found for the remaining pain tests. 
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Figure 11.  (A) Pressure pain thresholds, (B) individualized temperature and (C) pain ratings to achieve 
rating of 50/100, (P50) as well as (D) temporal summation of second pain aftersensations and (E) 
neurogenic flare results by gender.  Error bars = SEM.  * = p < .05.
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Figure 11. Continued. 
Differences in Affect 
Next, we wanted to assess the role of anxiety, depressive symptoms, and affect in 
binge- and withdrawal-induced pain sensitivity in individuals with a history of moderate 
or binge drinking.  Figure 12 depicts state anxiety (Fig. 12A), negative affect (Fig. 12B), 
and positive affect (Fig. 12C) collapsed across binge and moderate drinkers.  We found a 
main effect of state for state anxiety, F(1, 26) = 7.92, p = .009, and negative affect, F(1, 
26) = 7.61, p = .010, with participants in withdrawal reporting less anxiety and less
negative affect throughout the withdrawal state than when in abstinence.  There was a 
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trend toward a main effect of group for negative affect, F(1, 26) = 3.99, p = .056, with 
the binge group reporting moderately more negative affect over both states.  For positive 
affect at the beginning and end of each state, we found a main effect of time, F(1, 26) = 
10.39, p = .003, with positive affect decreasing over the course of each state.  No other 
main effects nor interactions were found including for depressive symptoms.  These 
results suggest that when in withdrawal, participants were less anxious and had less 
negative affect than when they were abstaining.  It also suggests that participants were 
less happy as each state progressed. 
Psychological Responses to Testing 
We wanted to assess the potential role of valence, arousal, and dominance during 
capsaicin and over the course of each state.  Figure 13 depicts valence (Fig. 13A), 
arousal (Fig. 13B), and dominance (Fig. 13C) during the capsaicin test.  We found main 
effects of time for valence, F(2.09, 54.46) = 12.77, p < .001, and dominance, F(3.11, 
Figure 12.  (A) State anxiety and (B) negative affect collapsed across the beginning and end of each 
drinking state as well as (C) positive affect collapsed across drinking states.  Error bars = SEM.  * = p < 
.05. 
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80.75) = 5.85, p = .001, indicating participants became less happy and less dominant 
over the course of each state.  There were no other main effects or interactions for 
valence or dominance.  There were also no main effects nor interactions for arousal 
during capsaicin, all ps > .08. 
Figure 13.  (A) Valence, and (B) Arousal, and (C) Dominance ratings during 45 minute capsaicin 
application in abstain and withdrawal states.  Error bars = SEM. 
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Figure 14 depicts valence (Fig. 14A), arousal (Fig. 14B), and dominance (Fig. 
14C) over the course of each drinking state.  We found main effects of state for valence, 
F(1, 24) = 5.42, p = .029, and dominance, F(1, 24) = 7.04, p = .014, with participants 
during the withdrawal state reporting being happier and more dominant over the course 
of the study.  We also found a main effect of time for valence, F(2.74, 65.75) = 12.33, p 
< .001, with participants generally becoming less happy over the course of each state.  In 
addition, for arousal, there was a State x Time x Group interaction, F(2.18, 50.21) = 
3.55, p = .032, with the binge group reporting increasing levels of arousal during the 
withdrawal state. 
Physiological Responses to Testing 
To determine whether participants with a history of binge drinking and 
withdrawal responded physiologically different to pain tests we investigated heart rate, 
skin conductance (a measure of perspiration rate), and respiration rate.  Figure 15 shows 
the heart rate in beats per minute (Fig. 15A), and interbeat interval (Fig. 15B), along 
with skin conductance (Fig. 15C), and respiration rate (Fig. 15D) collapsed across pain 
tests. 
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Figure 14.  (A) Valence, (B) arousal, and (C) dominance ratings throughout each drinking state.  Error 
bars = SEM.  * = p < .05. 
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Figure 15. (A) Heart rate in (A) beats per minute and (B) interbeat interval, (B) skin conductance level, 
and (C) respiration rate collapsed across before (Baseline), during (Pain Test), and after (Post) pressure 
pain threshold, topical capsaicin, and temporal summation of second pain procedures.  Error bars = SEM.  
* = p < .05.
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For heart rate in beats per minute, we found a trend towards a State x Time interaction, 
F(2, 54) = 5.85, p = .054, with participants during the withdrawal state showing 
relatively consistent heart rate during and after the pain tests while during the abstain 
state, they showed a slight increase in heart rate following the pain tests.  For heart rate 
interbeat interval, we found a main effect of state, F(1, 27) = 5.39, p = .028, suggesting 
participants during the withdrawal state had a shorter interbeat interval indicating a 
faster heart rate.  We also found a State x Time interaction for skin conductance level, 
F(1.79, 44.79) = 4.65, p = .018, suggesting that during the withdrawal state, participants 
skin conductance responses were consistently higher and did not decrease following the 
pain tests, particularly for the moderate group.  For respiration rate, we found a State x 
Time x Group interaction, F(2, 46) = 3.85, p = .028, suggesting that during the 
abstinence state, binge drinkers’ respiration rates were higher during the pain tests than 
moderate drinkers.  These results suggest that participants in withdrawal state 
experienced a greater physiological response throughout the study (heart rate) that did 
not dissipate after cessation of the test (skin conductance level). 
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CONCLUSION 
Binge drinking is a prevalent problem, in particular for young adults, that may 
lead to enhanced pain sensitivity.  In addition, self-medication of pain with alcohol may 
be a potential driver of further increases in pain and more extreme alcohol use.  Animal 
models of alcohol withdrawal-induced hyperalgesia indicate that multiple cycles of 
alcohol consumption and withdrawal results in an increase in muscle mechanical pain 
sensitivity mediated by alterations of the peripheral nociceptors.
25,27
  The current study
sought to examine mechanisms of binge withdrawal-induced hyperalgesia in humans.  
Using a mixed between-within-subjects design with naturally occurring alcohol use, the 
aims of this study were to understand 1) whether young adults with a history of binge 
drinking showed greater pressure pain muscle sensitivity, neurogenic inflammation, and 
central sensitization than moderate drinkers which would be exaggerated by withdrawal 
and 2) whether greater pain and inflammation would be associated with baseline 
epinephrine levels. 
Individuals tested during the withdrawal state reported reduced pressure pain 
threshold, indicating increased muscle pain sensitivity, when compared to testing during 
the abstain state.  In addition, participants tested during withdraw reported reduced 
cutaneous thermal pain sensitivity.  These effects of withdrawal were observed in both 
moderate and binge drinkers and the effect of withdrawal was not intensified in binge 
drinkers.  Importantly, this pattern was observed even though binge drinkers reported 
typically drinking more, drinking 4 drinks for women and 5 drinks for men, greater 
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symptoms of withdrawal and alcohol use disorders, higher perceived stressed, and 
heightened preoccupation with the rewarding aspects of alcohol. 
The study was unable to test the second aim that increased pain was associated 
with increased epinephrine and IL-6. 
Mechanical Muscle Hyperalgesia During Alcohol Withdrawal 
We found the general phenomenon of withdrawal-induced pressure pain muscle 
hyperalgesia in both binge and moderate drinkers.  This is consistent with previous 
findings of withdrawal-induced hyperalgesia in an animal model
25,27
 and in human binge
drinkers.
114
The current results differ in magnitude from a previous study that found 
significantly reduced muscle pressure pain threshold in binge drinkers compared to 
moderate drinkers that was exacerbated by withdrawal.
114
  Differences in study design
may explain the results.  You
114
 used a larger sample size (n = 23-50) with greater acute
hangover symptoms (binge withdrawal group M = 1.13) than used in the current study (n 
= 13-16; binge withdrawal state M = 0.83).  In the current study, our sample of binge 
drinkers was older (You et al.
114
 approximate Mage = 19 years; current study Mage = 22
years) and started drinking later (You et al.
114
 approximate Mage = 16-17 years; current
study Mage = 18.03years) than in the previous study where You et al.
114
 prescreened and
recruited participants from Introductory Psychology classes who were required to 
participate in the subject pool.  It is possible that more severe binge drinkers were harder 
to recruit in the present study because they are more likely to drop out of college and less 
likely to sign up for studies when they are not required.  Moreover, the current sample 
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may represent higher functioning binge drinkers because they self-selected to participate 
in an experiment that necessitated two visits each lasting 3.5 hours.  In contrast, You et 
al.
114
 used a between-subjects design that required only a single visit lasting 1.5 hours.
Despite differences in the magnitude of withdrawal symptoms and in the study design, 
we still found a selective withdrawal-induced mechanical hyperalgesia using a mixed 
between-within-subjects design.  The trend toward a main effect of group is consistent 
with You et al.
114
 and suggests that mechanical muscle hyperalgesia may be an effective
early indicator of abnormalities in pain processing. 
Cutaneous Thermal Hypoalgesia During Alcohol Withdrawal 
Although we did not find the expected cutaneous thermal hyperalgesia and 
temporal summation, our results are consistent with the general phenomenon of alcohol 
administration and withdrawal-induced cutaneous thermal hypoalgesia found in animal 
models.
17,47,50
  Interestingly, by including both mechanical and thermal pain assessments
in the same study, we found mechanical muscle hyperalgesia and thermal cutaneous 
hypoalgesia.  Exploratory analyses suggest these effects may be driven by the male 
participants.  Differential effects of mechanical and thermal stimuli were found in the 
amygdala in an animal model of diabetic peripheral neuropathy
72
 and in humans with
traumatic neuropathic pain.
41
  There are several testable explanations that may clarify
these divergent effects of withdrawal. 
One possible explanation is derived from the peripheral mechanisms found in an 
animal model of withdrawal-induced mechanical hyperalgesia.  Using this model of 
alcohol-induced peripheral neuropathy, researchers found mechanical hyperalgesia was 
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mediated by sensitization of C-fibers.
22
  In the early stages of alcohol use, the mechano-
sensitive subtype of C-fibers may mediate mechanical hyperalgesia.  With increasing use 
of alcohol, the immune system may become dysregulated resulting in a pro-
inflammatory state.
21,55
  In some individuals, an alcohol-induced increase in
inflammation and neuropathic damage resulting from early-stages of alcohol-induced 
peripheral neuropathy may lead to mechano-sensitive C-fibers becoming more sensitized 
to thermal stimuli.
89
  This would suggest mechanical hyperalgesia in early stages of
alcohol use and mechanical and thermal hyperalgesia in latter stages of alcohol use.  
Indeed, no difference in thermal sensitivity was found in young adults with a short 
history of alcohol use
114
 but increased thermal hyperalgesia was found in older adults
undergoing treatment for alcohol use.
49
  This explanation is speculative and would need
electrophysiological studies in animals to determine nociceptor subtype(s) affected by 
alcohol use.  However, this does not explain the diverging effects of mechanical and 
thermal sensitivity we found in the current study. 
A second explanation may be the type of skin at each location.  Pressure pain 
testing was conducted on hairy skin of the dorsal aspect of the foot while thermal 
temporal summation of second pain was conducted on glabrous skin (i.e., relatively 
absent of hair) of the palmar aspect of the hand.  Previous research has shown that 
glabrous skin has an increased thermal pain threshold, and may therefore be less 
sensitive to painful stimuli, than hairy skin.
43,97
  Since we tested thermal temporal
summation of second pain on the glabrous palm and found reduced pain (hypoalgesia) 
and tested pressure pain on the hairy skin of the foot and found hyperalgesia, our 
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divergent results may be due to pain sensitivity differences related to glabrous and hairy 
skin types.  Future studies should control for different skin types or parametrically study 
alcohol withdrawal-induced differences in pain sensitivity using different body 
locations. 
A third explanation may be the result of different temporal dynamics of muscle 
and cutaneous pain during alcohol withdrawal.  Peripheral neuropathies, including 
alcohol-induced peripheral neuropathy, are partially characterized by cutaneous pain 
with more recent evidence suggesting alterations in muscle pain.
3
  Hand-held
algometers, such as the one used in our study, are pressed into the muscle to activate 
nociceptors and is largely used to assess sensitivity of the muscle, while thermal devices 
such as the thermode the participant’s hand laid on top of in our study, are used to assess 
more cutaneous sensitivity.  Importantly, mechanical hyperalgesia of muscles and 
thermal hypoalgesia of cutaneous skin have been shown in trauma-induced neuropathic 
pain.
41,62
  One animal model of alcohol withdrawal-induced peripheral neuropathy
compared the time-course of mechanical cutaneous and muscle pain thresholds.
3
Mechanical cutaneous hyperalgesia was evident by day 8 of the alcohol withdrawal 
protocol while mechanical muscle hyperalgesia was delayed approximately one week 
until day 15.
3
  There was also a non-significant mechanical muscle hypoalgesia at day 5,
immediately following cessation of the first alcohol use cycle.
3
  Evidence that
neuropathies are associated with hyperalgesia and hypoalgesia along with the different 
temporal dynamics of muscle and cutaneous sensitivity in an animal model of alcohol 
withdrawal-induced peripheral neuropathy, suggest that the divergent effects we found 
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on mechanical (muscle) and thermal (cutaneous) pain may be due to different 
sensitivities of different types of pain sensitivity over the course of alcohol withdrawal. 
When female and male participants were analyzed separately, males showed 
muscle mechanical hyperalgesia and multiple indices of cutaneous thermal hypoalgesia 
while women in withdrawal showed more intense neurogenic flare.  Since the current 
study is underpowered for these exploratory analyses, these novel findings of gender 
need to be replicated in larger samples of women and men. 
Cutaneous Thermal Central Sensitization not Affected by Alcohol 
Similar to previous research in young binge drinkers with a short history of 
alcohol consumption that measured central sensitization using topical capsaicin-induced 
area of secondary hyperalgesia,
114
 we did not find enhanced temporal summation which
would have reflected central sensitization.  However, we did find a trend towards a State 
x Time interaction over the first five pulses during withdrawal with sensitization of 
temporal summation increasing over the five pulses, while during abstinence 
sensitization plateaued after the third pulse.  We also observed a visual trend towards 
binge drinkers reporting enhanced temporal summation during both abstinence and 
withdrawal states over all 10 cutaneous thermal pulses relative to moderate drinkers.  
However, these trends failed to reach significance, perhaps due to low statistical power.  
Previous research from our laboratory using a model of adversity-induced hyperalgesia, 
whose mechanisms are similar to alcohol withdrawal-induced hyperalgesia,
53,54
 found
enhanced temporal summation with a large sample size (n = 51-75 per group).
113
  In




 though we did find the same general trend as the larger study.  Given the trend
we found in our data for binge drinkers and drinkers in withdrawal reporting enhanced 
temporal summation, a larger sample size may have increased our power to find an 
effect. 
While our results in conjunction with previous studies suggest alcohol use may 
not uncover central sensitization using capsaicin or thermal modalities, the consistent 
finding of mechanical hyperalgesia suggests central sensitization may be modality-
specific and be uncovered using mechanical temporal summation.
68
  A third explanation
is the possibility that mechanical hyperalgesia may be mediated by more peripheral 
mechanisms, while thermal hypoalgesia may be mediated by more central mechanisms.  
Whether this central sensitization is dependent on or independent of increased afferent 
barrages from peripheral sensitization, binge withdrawal may sensitize other levels of 
the central nervous system.  Examples of sensitization in brain areas in neuropathic pain 
can be found in an animal model of arthritis that shows sensitization in the amygdala
72
and in an animal model of diabetic peripheral neuropathy that shows sensitization in the 
thalamus.
30
Based on the progression of alcohol-induced peripheral neuropathy, it is possible 
we might have found significant sensitization of temporal summation of second pain in a 
different body location in binge drinkers.  Alcohol-induced peripheral neuropathy 
presents in chronic alcohol users and is characterized by a distal axonopathy where 
axons in the distal extremities, particularly the lower extremities and to a lesser extent 
the upper extremities, die back.
57
  Therefore, the feet may show increased sensitivity to
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early signs of peripheral neuropathy than the hands.  Alcohol-induced peripheral 
neuropathy has been shown in adults in their 20s and older, though increasing age and 
longer duration of alcohol abuse were associated with having neuropathic 
symptoms.
100,115
  Based on prior work in alcohol withdrawal-induced mechanical
hyperalgesia in animal models,
3,25,27
 early neuropathic changes may be present in young
adult binge drinkers.  Therefore, in light of the progression of alcohol-induced peripheral 
neuropathy and animal models of withdrawal-induced hyperalgesia after short term 
alcohol use, it is possible we may have observed enhanced cutaneous thermal temporal 
summation of second pain in binge drinkers if we tested on the foot, as we did with 
muscle mechanical pain testing. 
We did find decreased aftersensations over time in the withdrawal state 
compared to the abstinence state.  A more rapid return to baseline during the withdrawal 
state corroborates the thermal hypoalgesia we found in the more static measures of 
thermal sensitivity. 
Capsaicin-Induced Neurogenic Inflammation and Spontaneous Pain not Affected 
by Alcohol 
Previous research showed binge drinkers had an increased area of flare during 
withdrawal while moderate drinkers showed a decreased area of flare during 
withdrawal.
114
  That the current study showed no difference may be due to less acute
hangover symptoms compared to the previous study.  This suggests neurogenic 
inflammation may be related to a combination of drinking history and subjective acute 
withdrawal symptoms. 
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Issues in Translating Animal Research to Humans 
Animal studies have typically used either quickly acting intraperitoneal 
administration of alcohol
17,32,47,50,70,75
 or a 6.5% alcohol diet
27,35
 with the latter resulting
in a blood alcohol content approximately 3.84 times higher than the legal limit in the 
U.S. (307.7mg/dL in animals compared to 80mg/dL in humans).  In the current study, 
individuals were unlikely to have achieved levels similar to the animal models and 
therefore the levels of drinking in the animal studies may have had stronger effects on 
pain sensitivity and may therefore follow a different time course of intoxication and 
withdrawal that does not directly translate to humans. 
Furthermore, animal studies have found effects without typically following the 
definition of binge drinking used by the NIAAA (0.08% BAC or 4 or 5 drinks [i.e., 4/5] 
in approximately 2 hours for women and men, respectively) and other levels of drinking.  
That effects of withdrawal on pain sensitivity can be found regardless of NIAAA levels 
of binge drinking is supported by the rationale behind the binge drinking definition.  The 
0.08% BAC was determined by the resulting cognitive and motor impairments that 
hinder driving ability.
82
  Even this distinction of 0.08% BAC is flexible as a recent
publication from the U.S. National Transportation Safety Board recommended lowering 
the legal BAC limit in the US to 0.05%.
46
  Indeed, previous research in humans using
experimental administration of alcohol to reach 0.08% BAC was insufficient to uncover 
hyperalgesia or enhanced central sensitization.
114
  While the current 0.08% or 4/5 drink
definition of binge drinking represents important cognitive and motor impairments and is 
effective for establishing categories for laws and research, it may not inherently 
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represent a threshold for pain sensitivity.  Future studies would need to determine such a 
threshold or if continuous measures of alcohol are sufficient. 
Clinical Implications 
The current study found mechanical hyperalgesia and thermal hypoalgesia in the 
withdrawal state of alcohol consumption regardless of drinking category.  This suggests 
that clinicians may want to focus on withdrawal from a continuum of alcohol 
consumption.  This pain phenotype may also be a relatively quick way for doctors to 
have a quantitative measure for individuals at risk for alcohol withdrawal-induced 
hyperalgesia and further increases in substance use by potentially comparing pain ratings 




While we found novel mechanical hyperalgesia and thermal hypoalgesia in 
humans using a mixed between-within-subject design, the time-course of withdrawal 
experienced by our participants may have limited our ability to see the hypothesized 
effects. 
The binge drinkers in our study showed greater symptoms of alcohol use (higher 
AUDIT scores, more drinking, and more typical hangover symptoms), however the lack 
of difference in acute hangover symptoms in binge drinkers compared to moderate 
drinkers may have limited our statistical power in finding group differences or Group x 
State interactions in mechanical hyperalgesia, neurogenic flare, epinephrine, and IL-6. 
In our study, participants arrived first in the control state of abstinence and in a 
separate visit were in the experimental state of withdrawal.  This may have resulted in 
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participants being more anxious during the first state (abstinence) resulting in stress-
induced hyperalgesia and more relaxed during the second state (withdrawal).  Future 
studies should run a counter-balanced design to determine if order of visits has an effect 
on alcohol withdrawal-induced pain sensitivity. 
Future Directions 
While our study helps advance the literature on alcohol and binge withdrawal-
induced hyperalgesia in humans, it also suggests future studies.  The divergent effects of 
muscle mechanical hyperalgesia and cutaneous thermal hypoalgesia as well as self-
report and psychophysiological measures of affect and arousal may be the result of 
different time courses for alcohol withdrawal’s effects.  As previously discussed, muscle 
mechanical sensitivity and cutaneous thermal sensitivity may be dependent on the time 
course of withdrawal.  We also found positive self-report potentially resulting from a 
decreasing “a” process and increased psychophysiological arousal potentially from an 
increasing “b” process.  It is possible that self-report negative affect may emerge at a 
later time point in withdrawal than we assessed.  Therefore, future studies should 
parametrically investigate the time course of alcohol use and withdrawal on different 
measures of pain, affect, and arousal. 
Future studies should also systematically vary the level of severity of alcohol use 
and age participants began drinking along with their drinking history.  In younger 
individuals or those with a short drinking history, a longitudinal study should be 
conducted to determine how their alcohol use and drinking history predict their risk of 
developing increased pain sensitivity and alcohol use disorders.  One particular subset of 
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individuals that should be included in separate analyses is people with clinical alcohol 
use disorders showing withdrawal-related symptoms. 
Differences in opioidergic function, particularly of the mu opioid subtype, should 
be investigated.  Previous research in humans showed greater binding of endogenous 
endorphins to mu opioid receptors in the nucleus accumbens and orbitofrontal cortex 
was related to greater subjective pleasure.
69
  More pleasure during intoxication may help
drive the initial stages of alcohol use.  In addition, research has shown that the presence 
of a single nucleotide polymorphism in the opioid receptor mu 1 (OPRM1) gene 
associated with a decreased response to opioids predicted decreased pain in women 
following sexual assault
6
 or a motor vehicle accident in women with peritraumatic
distress.
63
  This effect is sexually dimorphic as men with the same polymorphism
showed increased pain following a motor vehicle accident.
63
  Future studies should
include measures of opioid response in individuals with varieties of drinking history as 
this may not only affect the initial stages of alcohol use but the development of alcohol 
withdrawal-induced hyperalgesia. 
Summary 
The current study used a mixed between- and within-subjects design comparing 
moderate drinkers and binge drinkers during the abstinence and withdrawal states of 
alcohol use.  Binge drinkers reported more typical alcohol use and more alcohol use 
prior to the withdrawal state as well as reporting more typical hangover symptoms and 
alcohol use disorder symptoms.  We found participants in the withdrawal state reported 
muscle mechanical hyperalgesia and cutaneous thermal hypoalgesia when compared to 
69 
the abstain visit, regardless of drinking group.  Participants in the withdrawal state also 
reported more dominance, less anxiety, and less negative affect but greater 
cardiovascular and respiratory activity than when they were in the abstinence state.  
Several hypotheses for future research were presented along with recommendations for 
future studies.  This research suggests the divergent effects of alcohol on pain sensitivity 
may depend on the specific modality being tested.  This research suggests that the 




1. van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W: Ranking the
harm of alcohol, tobacco and illicit drugs for the individual and the population.
Eur Addict Res 16:202–207, 2010.
2. Adinoff B, Iranmanesh A, Veldhuis J, Fisher L: Disturbances of the stress
response: the role of the HPA axis during alcohol withdrawal and abstinence.
Alcohol Health Res World 22:67–72, 1998.
3. Alvarez P, Ferrari LF, Levine JD: Muscle pain in models of chemotherapy-
induced and alcohol-induced peripheral neuropathy. Ann Neurol 70:101–109,
2011.
4. Apkarian AV, Bushnell MC, Treede R-D, Zubieta J-K: Human brain mechanisms
of pain perception and regulation in health and disease. Eur J Pain 9:463–484,
2005.
5. Apkarian AV, Neugebauer V, Koob G, Edwards S, Levine JD, Ferrari L, Egli M,
Regunathan S: Neural mechanisms of pain and alcohol dependence. Pharmacol
Biochem Behav 112:34–41, 2013.
6. Ballina LE, Ulirsch JC, Soward AC, Rossi C, Rotolo S, Linnstaedt SD, Heafner
T, Foley KA, Batts J, Collette R, Holbrook D, Zelman S, McLean SA: μ-Opioid
receptor gene A118G polymorphism predicts pain recovery after sexual assault. J
Pain 14:165–171, 2013.
71 
7. Baron R, Hans G, Dickenson AH: Peripheral input and its importance for central
sensitization. Ann Neurol 74:630–636, 2013.
8. Bartley EJ, Fillingim RB: Sex differences in pain: a brief review of clinical and
experimental findings. Br J Anaesth 111:52–58, 2013.
9. Bau PFD, Moraes RS, Bau CHD, Ferlin EL, Rosito GA, Fuchs FD: Acute
ingestion of alcohol and cardiac autonomic modulation in healthy volunteers.
Alcohol 45:123–129, 2011.
10. BIOPAC Systems Inc.: Application Note 233: Heart Rate Variability—Preparing
Data for Analysis Using AcqKnowledge [Internet]. BIOPAC Systems, Inc.; 2016
Jan. Available from: https://www.biopac.com/application-note/heart-rate-
variability-preparing-data-for-analysis/
11. BIOPAC Systems Inc.: Respiration Recording [Internet]. Respiration Recording.
[cited 2017 Mar 20]. Available from: https://www.biopac.com/knowledge-
base/respiration-recording/
12. Bosma RL, Ameli Mojarad E, Leung L, Pukall C, Staud R, Stroman PW: Neural
correlates of temporal summation of second pain in the human brainstem and
spinal cord. Hum Brain Mapp 36:5038–5050, 2015.
13. Bosma RL, Mojarad EA, Leung L, Pukall C, Staud R, Stroman PW: FMRI of
spinal and supra-spinal correlates of temporal pain summation in fibromyalgia
patients. Hum Brain Mapp 37:1349–1360, 2016.
14. Bradley MM, Lang PJ: Measuring emotion: the Self-Assessment Manikin and the
Semantic Differential. J Behav Ther Exp Psychiatry 25:49–59, 1994.
72 
15. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I: Calcitonin gene-
related peptide is a potent vasodilator. Nature 313:54–56, 1985.
16. Bremner JD, Vermetten E, Mazure CM: Development and preliminary
psychometric properties of an instrument for the measurement of childhood
trauma: the Early Trauma Inventory. Depress Anxiety 12:1–12, 2000.
17. Campbell VC, Taylor RE, Tizabi Y: Antinociceptive effects of alcohol and
nicotine: involvement of the opioid system. Brain Res 1097:71–77, 2006.
18. Carver CS: You want to measure coping but your protocol’s too long: consider
the brief COPE. Int J Behav Med 4:92–100, 1997.
19. Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J
Health Soc Behav 24:385–396, 1983.
20. Collins RL, Parks GA, Marlatt GA: Social determinants of alcohol consumption:
the effects of social interaction and model status on the self-administration of
alcohol. J Consult Clin Psychol 53:189–200, 1985.
21. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L,
Szabo G, Wheeler M, Zou J: Cytokines and Alcohol. Alcoholism Clin Exp Res
30:720–730, 2006.
22. Dina OA, Barletta J, Chen X, Mutero A, Martin A, Messing RO, Levine JD: Key
role for the epsilon isoform of protein kinase C in painful alcoholic neuropathy in
the rat. J Neurosci 20:8614–8619, 2000.
73 
23. Dina OA, Gear RW, Messing RO, Levine JD: Severity of alcohol-induced painful
peripheral neuropathy in female rats: role of estrogen and protein kinase (A and
Cepsilon). Neuroscience 145:350–356, 2007.
24. Dina OA, Green PG, Levine JD: Role of interleukin-6 in chronic muscle
hyperalgesic priming. Neuroscience 152:521–525, 2008.
25. Dina OA, Khasar SG, Alessandri-Haber N, Green PG, Messing RO, Levine JD:
Alcohol-induced stress in painful alcoholic neuropathy. Eur J Neurosci 27:83–92,
2008.
26. Dina OA, Levine JD, Green PG: Enhanced cytokine-induced mechanical
hyperalgesia in skeletal muscle produced by a novel mechanism in rats exposed
to unpredictable sound stress. Eur J Pain 15:796–800, 2011.
27. Dina OA, Messing RO, Levine JD: Ethanol withdrawal induces hyperalgesia
mediated by PKCepsilon. Eur J Neurosci 24:197–204, 2006.
28. Egli M, Koob GF, Edwards S: Alcohol dependence as a chronic pain disorder.
Neurosci Biobehav Rev 36:2179–2192, 2012.
29. Fang L, McNeil S: Is there a relationship between adverse childhood experiences
and problem drinking behaviors? Findings from a population-based sample.
Public Health 150:34–42, 2017.
30. Fischer TZ, Tan AM, Waxman SG: Thalamic neuron hyperexcitability and
enlarged receptive fields in the STZ model of diabetic pain. Brain Res 1268:154–
161, 2009.
74 
31. Foltran F, Gregori D, Franchin L, Verduci E, Giovannini M: Effect of alcohol
consumption in prenatal life, childhood, and adolescence on child development.
Nutr Rev 69:642–659, 2011.
32. Franklin KB, Abbott FV: Pentobarbital, diazepam, and ethanol abolish the
interphase diminution of pain in the formalin test: evidence for pain modulation
by GABAA receptors. Pharmacol Biochem Behav 46:661–666, 1993.
33. Friedman HJ, Bass MB, Lester D: Ethanol-induced analgesia in rats selectively
bred for ethanol sensitivity. Pharmacol Biochem Behav 13:773–776, 1980.
34. Funk CK, O’Dell LE, Crawford EF, Koob GF: Corticotropin-releasing factor
within the central nucleus of the amygdala mediates enhanced ethanol self-
administration in withdrawn, ethanol-dependent rats. J Neurosci 26:11324–
11332, 2006.
35. Gatch MB, Lal H: Effects of ethanol and ethanol withdrawal on nociception in
rats. Alcohol Clin Exp Res 23:328–333, 1999.
36. Gatch MB: Ethanol withdrawal and hyperalgesia. Curr Drug Abuse Rev 2:41–50,
2009.
37. Gatch MB: Nitrendipine blocks the nociceptive effects of chronically
administered ethanol. Alcohol Clin Exp Res 26:1181–1187, 2002.
38. George O, Koob GF: Individual differences in the neuropsychopathology of
addiction. Dialogues Clin Neurosci 19:217–229, 2017.
75 
39. Goebel JR, Compton P, Zubkoff L, Lanto A, Asch SM, Sherbourne CD,
Shugarman L, Lorenz KA: Prescription sharing, alcohol use, and street drug use
to manage pain among veterans. J Pain Symptom Manage 41:848–858, 2011.
40. Gomez A, Conde A, Santana JM, Jorrin A: Diagnostic usefulness of brief
versions of alcohol use disorders identification test (AUDIT) for detecting
hazardous drinkers in primary care settings. J Stud Alcohol 66:305–308, 2005.
41. Gottrup H, Nielsen J, Arendt-Nielsen L, Jensen TS: The relationship between
sensory thresholds and mechanical hyperalgesia in nerve injury. Pain 75:321–
329, 1998.
42. Granot M: Can we predict persistent postoperative pain by testing preoperative
experimental pain? Curr Opin Anaesthesiol 22:425–430, 2009.
43. Granovsky Y, Matre D, Sokolik A, Lorenz J, Casey KL: Thermoreceptive
innervation of human glabrous and hairy skin: a contact heat evoked potential
analysis. Pain 115:238–247, 2005.
44. Green AQ, Krishnan ST, Rayman G: C-fiber function assessed by the laser
doppler imager flare technique and acetylcholine iontophoresis. Muscle Nerve
40:985–991, 2009.
45. Hashimoto JG, Wiren KM: Neurotoxic consequences of chronic alcohol
withdrawal: expression profiling reveals importance of gender over withdrawal
severity. Neuropsychopharmacology 33:1084–1096, 2008.
76 
46. Hersman DAP, Hart CA, Sumwalt RL, Rosekind MR, Weener EF: Safety
Recommendation H-13-005. Washington, D.C.: National Transportation Safety
Board; 2013 Jun. Report No.: Safety Recommendation H-13-005.
47. Holloway FA, Miller JM, King DA, Bedingfield JB: Delayed ethanol effects on
physiological and behavioral indices in the rat. Alcohol 10:511–519, 1993.
48. Jakubczyk A, Ilgen MA, Kopera M, Krasowska A, Klimkiewicz A, Bohnert A,
Blow FC, Brower KJ, Wojnar M: Reductions in physical pain predict lower risk
of relapse following alcohol treatment. Drug Alcohol Depend 158:167–171,
2016.
49. Jochum T, Boettger MK, Burkhardt C, Juckel G, Bär K-J: Increased pain
sensitivity in alcohol withdrawal syndrome. Eur J Pain 14:713–718, 2010.
50. Jørgensen HA, Hole K: Does ethanol stimulate brain opiate receptors? Studies on
receptor binding and naloxone inhibition of ethanol-induced effects. Eur J
Pharmacol 75:223–229, 1981.
51. Katz WA: Musculoskeletal pain and its socioeconomic implications. Clin
Rheumatol 21 Suppl 1:S2–4, 2002.
52. Keene JR, Clayton RB, Berke CK, Loof T, Bolls PD: On the Use of Beats-Per-
Minute and Interbeat Interval in the Analysis of Cardiac Responses to Mediated
Messages. Comm Res Rep 34:265–274, 2017.
53. Khasar SG, Burkham J, Dina OA, Brown AS, Bogen O, Alessandri-Haber N,
Green PG, Reichling DB, Levine JD: Stress induces a switch of intracellular
77 
signaling in sensory neurons in a model of generalized pain. J Neurosci 28:5721–
5730, 2008.  
54. Khasar SG, Dina OA, Green PG, Levine JD: Sound stress-induced long-term
enhancement of mechanical hyperalgesia in rats is maintained by
sympathoadrenal catecholamines. J Pain 10:1073–1077, 2009.
55. Kim D-J, Kim W, Yoon S-J, Choi B-M, Kim J-S, Go HJ, Kim Y-K, Jeong J:
Effects of alcohol hangover on cytokine production in healthy subjects. Alcohol
31:167–170, 2003.
56. King AC, de Wit H, McNamara PJ, Cao D: Rewarding, stimulant, and sedative
alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry
68:389–399, 2011.
57. Koike H, Sobue G: Alcoholic neuropathy. Curr Opin Neurol 19:481–486, 2006.
58. Koob GF, Le Moal M: Addiction and the brain antireward system. Annu Rev
Psychol 59:29–53, 2008.
59. Koob GF: Brain stress systems in the amygdala and addiction. Brain Res
1293:61–75, 2009.
60. Koob GF: The dark side of emotion: the addiction perspective. Eur J Pharmacol
753:73–87, 2015.
61. Law EF, Bromberg MH, Noel M, Groenewald C, Murphy LK, Palermo TM:
Alcohol and tobacco use in youth with and without chronic pain. J Pediatr
Psychol 40:509–516, 2015.
 78 
62.  Lindblom U, Verrillo RT: Sensory functions in chronic neuralgia. J Neurol 
Neurosurg Psychiatry 42:422–435, 1979.  
63.  Linnstaedt SD, Hu J, Bortsov AV, Soward AC, Swor R, Jones J, Lee D, Peak D, 
Domeier R, Rathlev N, Hendry P, McLean SA: μ-Opioid Receptor Gene A118 G 
Variants and Persistent Pain Symptoms Among Men and Women Experiencing 
Motor Vehicle Collision. J Pain 16:637–644, 2015.  
64.  Magerl W, Krumova EK, Baron R, Tölle T, Treede R-D, Maier C: Reference data 
for quantitative sensory testing (QST): refined stratification for age and a novel 
method for statistical comparison of group data. Pain 151:598–605, 2010.  
65.  Marteau TM, Bekker H: The development of a six-item short-form of the state 
scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 
31 ( Pt 3):301–306, 1992.  
66.  Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM: Development and 
validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res 17:140–
146, 1993.  
67.  Martinotti G, Di Nicola M, Tedeschi D, Callea A, Di Giannantonio M, Janiri L, 
Craving Study Group: Craving Typology Questionnaire (CTQ): a scale for 
alcohol craving in normal controls and alcoholics. Compr Psychiatry 54:925–932, 
2013.  
68.  Mathur VA, Kiley KB, Haywood C, Bediako SM, Lanzkron S, Carroll CP, 
Buenaver LF, Pejsa M, Edwards RR, Haythornthwaite JA, Campbell CM: 
Multiple Levels of Suffering: Discrimination in Health-Care Settings is 
79 
Associated With Enhanced Laboratory Pain Sensitivity in Sickle Cell Disease. 
Clin J Pain 32:1076–1085, 2016.  
69. Mitchell JM, O’Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL: Alcohol
consumption induces endogenous opioid release in the human orbitofrontal cortex
and nucleus accumbens. Sci Transl Med 4:116ra6, 2012.
70. Mogil JS, Marek P, Yirmiya R, Balian H, Sadowski B, Taylor AN, Liebeskind
JC: Antagonism of the non-opioid component of ethanol-induced analgesia by the
NMDA receptor antagonist MK-801. Brain Res 602:126–130, 1993.
71. National Institute on Alcohol Abuse and Alcoholism: NIAAA council approves
definition of binge drinking. NIAAA Newsletter :3, 2004.
72. Neugebauer V, Li W: Differential sensitization of amygdala neurons to afferent
inputs in a model of arthritic pain. J Neurophysiol 89:716–727, 2003.
73. Nutt DJ, King LA, Phillips LD, Independent Scientific Committee on Drugs:
Drug harms in the UK: a multicriteria decision analysis. Lancet 376:1558–1565,
2010.
74. Perrino AC, Ralevski E, Acampora G, Edgecombe J, Limoncelli D, Petrakis IL:
Ethanol and pain sensitivity: effects in healthy subjects using an acute pain
paradigm. Alcohol Clin Exp Res 32:952–958, 2008.
75. Pohorecky LA, Shah P: Ethanol-induced analgesia. Life Sci 41:1289–1295, 1987.
76. Portero-Tresserra M, Gracia-Rubio I, Cantacorps L, Pozo OJ, Gómez-Gómez A,
Pastor A, López-Arnau R, de la Torre R, Valverde O: Maternal separation
increases alcohol-drinking behaviour and reduces endocannabinoid levels in the
80 
mouse striatum and prefrontal cortex. Eur Neuropsychopharmacol 28:499–512, 
2018.  
77. Price DD, McGrath PA, Rafii A, Buckingham B: The validation of visual
analogue scales as ratio scale measures for chronic and experimental pain. Pain
17:45–56, 1983.
78. Radloff LS: The CES-D Scale: A Self-Report Depression Scale for Research in
the General Population. Appl Psychol Meas 1:385–401, 1977.
79. Randall LO, Selitto JJ: A method for measurement of analgesic activity on
inflamed tissue. Arch Int Pharmacodyn Ther 111:409–419, 1957.
80. Reddan MC, Wager TD: Modeling Pain Using fMRI: From Regions to
Biomarkers. Neurosci Bull 34:208–215, 2018.
81. Riley JL, King C: Self-report of alcohol use for pain in a multi-ethnic community
sample. J Pain 10:944–952, 2009.
82. Rodriguez-Iglesias C, Wiliszowski CH, Lacey JH: Legislative History of .08 Per
Se Laws. Springfield, VA: National Technical Information Service; 2001 Jul.
Report No.: DOT HS 809 286.
83. Rohsenow DJ, Howland J, Minsky SJ, Greece J, Almeida A, Roehrs TA: The
Acute Hangover Scale: A new measure of immediate hangover symptoms. Addict
Behav 32:1314–1320, 2007.
84. Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, Binder A, Birbaumer
N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer
GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet
81 
M, Wasserka B: Quantitative sensory testing in the German Research Network on 
Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 
123:231–243, 2006.  
85. Rosenkranz MA, Davidson RJ, Maccoon DG, Sheridan JF, Kalin NH, Lutz A: A
comparison of mindfulness-based stress reduction and an active control in
modulation of neurogenic inflammation. Brain Behav Immun 27:174–184, 2013.
86. Rosenkranz MA, Lutz A, Perlman DM, Bachhuber DRW, Schuyler BS,
MacCoon DG, Davidson RJ: Reduced stress and inflammatory responsiveness in
experienced meditators compared to a matched healthy control group.
Psychoneuroendocr 68:117–125, 2016.
87. Saria A: Substance P in sensory nerve fibres contributes to the development of
oedema in the rat hind paw after thermal injury. Br J Pharmacol 82:217–222,
1984.
88. Sauer SK, Reeh PW, Bove GM: Noxious heat-induced CGRP release from rat
sciatic nerve axons in vitro. Eur J Neurosci 14:1203–1208, 2001.
89. Schmidt R, Schmelz M, Forster C, Ringkamp M, Torebjörk E, Handwerker H:
Novel classes of responsive and unresponsive C nociceptors in human skin. J
Neurosci 15:333–341, 1995.
90. Singleton E, Tiffany S, Henningfield J, editors: Development and validation of a
new questionnaire to assess craving for alcohol: problems of drug dependence.
1994.
 82 
91.  Slutske WS, Piasecki TM, Hunt-Carter EE: Development and initial validation of 
the Hangover Symptoms Scale: prevalence and correlates of Hangover Symptoms 
in college students. Alcohol Clin Exp Res 27:1442–1450, 2003.  
92.  Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X: Contribution of excessive 
alcohol consumption to deaths and years of potential life lost in the United States. 
Prev Chronic Dis 11:E109, 2014.  
93.  Staud R, Craggs JG, Robinson ME, Perlstein WM, Price DD: Brain activity 
related to temporal summation of C-fiber evoked pain. Pain 129:130–142, 2007.  
94.  Staud R, Robinson ME, Price DD: Temporal summation of second pain and its 
maintenance are useful for characterizing widespread central sensitization of 
fibromyalgia patients. J Pain 8:893–901, 2007.  
95.  Stewart SH, Finn PR, Pihl RO: A dose-response study of the effects of alcohol on 
the perceptions of pain and discomfort due to electric shock in men at high 
familial-genetic risk for alcoholism. Psychopharmacol 119:261–267, 1995.  
96.  Substance Abuse and Mental Health Services Administration: Key Substance Use 
and Mental Health Indicators in the United States: Results from the 2016 
National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral 
Health Statistics and Quality, Substance Abuse and Mental Health Services 
Administration; 2017. Report No.: HHS Publication No. SMA 17-5044, NSDUH 
Series H-52.  
97.  Taylor DJ, McGillis SLB, Greenspan JD: Body site variation of heat pain 
sensitivity. Somatosens Mot Res 10:455–465, 1993.  
83 
98. Thelin Bronner KB, Wennberg P, Källmén H, Schult M-LB: Alcohol habits in
patients with long-term musculoskeletal pain: comparison with a matched control
group from the general population. Int J Rehabil Res 35:130–137, 2012.
99. Trevisani M, Gazzieri D, Benvenuti F, Campi B, Dinh QT, Groneberg DA,
Rigoni M, Emonds-Alt X, Creminon C, Fischer A, Geppetti P, Harrison S:
Ethanol causes inflammation in the airways by a neurogenic and TRPV1-
dependent mechanism. J Pharmacol Exp Ther 309:1167–1173, 2004.
100. Vittadini G, Buonocore M, Colli G, Terzi M, Fonte R, Biscaldi G: Alcoholic
polyneuropathy: a clinical and epidemiological study. Alcohol Alcohol 36:393–
400, 2001.
101. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo C-W, Kross E: An fMRI-
based neurologic signature of physical pain. N Engl J Med 368:1388–1397, 2013.
102. Walls SA, Rosenwasser AM, Devaud LL: Sex and regional differences in effects
of chronic intermittent ethanol exposure on subsequent excitotoxic challenges in
hippocampal slice cultures. Neurosci Lett 550:6–11, 2013.
103. Watson D, Clark LA, Tellegen A: Development and validation of brief measures
of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–
1070, 1988.
104. Whiteside SP, Lynam DR, Miller JD, Reynolds SK: Validation of the UPPS
impulsive behaviour scale: a four-factor model of impulsivity. Eur J Pers 19:559–
574, 2005.
 84 
105.  Wilhelm CJ, Hashimoto JG, Roberts ML, Bloom SH, Beard DK, Wiren KM: 
Females uniquely vulnerable to alcohol-induced neurotoxicity show altered 
glucocorticoid signaling. Brain Res 1601:102–116, 2015.  
106.  Witkiewitz K, Vowles KE, McCallion E, Frohe T, Kirouac M, Maisto SA: Pain 
as a predictor of heavy drinking and any drinking lapses in the COMBINE study 
and the UK Alcohol Treatment Trial. Addiction 110:1262–1271, 2015.  
107.  Woolf CJ: Central sensitization: implications for the diagnosis and treatment of 
pain. Pain 152:S2–15, 2011.  
108.  Woolf CJ: Evidence for a central component of post-injury pain hypersensitivity. 
Nature 306:686–688, 1983.  
109.  World Health Organization: Global status report on alcohol and health 2014. 
Luxembourg: World Health Organization; 2014.  
110.  Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, Best 
L-A, Granot M: Prediction of chronic post-operative pain: pre-operative DNIC 
testing identifies patients at risk. Pain 138:22–28, 2008.  
111.  You DS, Haney R, Albu S, Meagher MW: Generalized Pain Sensitization and 
Endogenous Oxytocin in Individuals With Symptoms of Migraine: A Cross-
Sectional Study. Headache 58:62–77, 2018.  
112.  You DS, Meagher MW: Childhood Adversity and Pain Facilitation. Psychosom 
Med.  
113.  You DS, Meagher MW: Childhood adversity and pain sensitization. Psychosom 
Med 78:1084–1093, 2016.  
85 
114. You DS: Alcohol Withdrawal-Induced Hyperalgesia in Young Adult Binge
Drinkers [Doctoral dissertation]. Texas A&M University; 2016.
115. Zambelis T, Karandreas N, Tzavellas E, Kokotis P, Liappas J: Large and small
fiber neuropathy in chronic alcohol-dependent subjects. J Peripher Nerv Syst
10:375–381, 2005.
